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Abstract
Melanoma is an aggressive skin cancer that plagues Western populations. Current
treatments such as surgery, chemotherapy, and high-dose radiation have had some
success, but often fail in treating late stage metastatic melanoma. Immunotherapies have
been successful in treating a small percentage of late stage patients, but these treatments
do not provide a long-lasting response to effectively clear the tumor. Therefore, current
studies have been investigating whether combining common treatments with
immunotherapies would provide the necessary boost to further improve tumor killing. An
optimum presentation of HLA class II proteins is essential for the activation of CD4+ T
cells, which provide a sustained killing of malignant tumors by activating cytotoxic
CD8+ T cells. Our laboratory has recently shown that the induction of GammaInterferon-inducible Lysosomal Thiol reductase (GILT) in melanoma favors HLA class II
antigen processing and CD4+ T cells recognition of tumors. The present study examined
the role of GILT in generating a greater pool of reduced and functional epitopes for HLA
class II-mediated presentation and recognition of CD4+ T cells. This study also
investigated the mechanisms by which GILT expression negatively regulates a
tumorigenic molecule, paired box 3 (PAX3), in melanoma cells; and how regulation of
PAX3 leads to melanoma cell sensitization to radiation and chemoimmunotherapy.
Additionally, this study tested a chemotherapeutic agent (GA-DM), which induced
apoptosis in a p53-dependent pathway and altered GILT, PAX3, and HLA class II
molecules in melanoma cells in vitro. Interestingly, the combination of radiation and GADM treatment in vivo in the B16 melanoma mouse model displayed increased survival
iii

and decreased tumor volume among treatment groups. Based upon the results of this
study, the combination treatment of radiation and GA-DM could be utilized to eliminate
melanoma cells while boosting immune responses in the host. Understanding the
molecular mechanisms of GILT-mediated downregulation of PAX3 as well as the
radiation and GA-DM treatment death pathway could lead to a new target for devising
novel chemoimmunotherapeutics for late stage metastatic melanoma.
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Chapter 1: Background and Review of Relevant Literature
Melanoma Origin and Progression
Melanoma is one of the fastest growing cancers in the world, with an incidence
increasing more quickly than any other cancer (except lung cancer in women) [1]. It was
responsible for an estimated 76,000 cases of skin cancer in 2014 [2]. It accounts for
about 9,700 of 13,000 skin cancer-related deaths each year [1].

Many cases are

underreported, and incidence rates may be higher than what is projected.
Melanoma is a cancer that arises from melanocytes, which are the normal
pigment-producing cells in the skin [3]. These cells are derived from the neural crest
during embryonic development [4]. Neural crest precursor cells then undergo
melanocyte migration, survival, and differentiation, in the presence of β-catenin [5].
These processes rely heavily on the Wnt signaling pathway, c-KIT receptor tyrosine
kinase, and transcription factors like PAX3 and MITF [6, 7]. These and other pathways
can be modified and possibly reactivated after the transformation from melanocyte to
melanoma [8-10].
In normal adult skin, melanocytes are found at the junction of the dermis and
epidermis, just superficial to the basement membrane [3]. Melanocytes exist primarily as
individual cells within the epidermis, but instead of forming interactions with each other,
melanocytes form heterotypic interactions with nearby keratinocytes, the predominant
cell type in the skin [3]. Melanocytes within the epidermis acquire some epithelial traits,
such as the formation of adherens junctions to neighboring keratinocytes [11].
Progression from normal melanocytes into melanoma has multiple steps.
1

Melanoma is thought to arise in one of two ways: (1) with no visible precursor lesion or
(2) in association with a benign melanocytic proliferation called a nevus (or mole) [11].
In the progression model of melanoma, the primary step is the formation of the nevus,
where proliferation and aggregation of melanocytes to form nests at the epidermal/dermal
junction or within the dermis [12]. Next, the nevus progresses to melanoma in situ,
which is confined to the epidermal/dermal junction. Melanomas that do not develop from
a precursor lesion may be first detected in this stage [13]. The following step in the
progression model is where invasive melanoma cells grow into the dermis where they
interact with multiple cell types and have access to vasculature [3]. The final step is
metastatic disease, where malignant cells have traveled from the primary site and
established disease at distant sites in the body. The most common sites of metastases in
malignant melanoma are lymph nodes, lungs, liver, and brain [12, 13]. Metastases have
also been found in the GI tract as well as bone [3].

Risk Factors
Major risk factors for developing melanoma include early childhood sun
exposure, fair hair and complexion, tanning bed use, high amounts of common
melanocytic nevi, immunosuppression, and a family history [14]. There are multiple
genetic loci that have been identified in melanoma risk, such as CDKN2A, CDK4,
MC1R, MITF, BRAF, and many others. Mutations in BRAF have been found in about
40-70% of melanomas, while CDK4 has been identified in about 10% [15, 16].
Cyclin-dependent kinase N2A (CDK2NA) expression has been found in both
2

melanoma and dysplastic nevi [17]. The CDKN2A gene encodes the p16INK4a and p14ARF
proteins, which are both tumor suppressors with important roles in the cell cycle and
apoptosis regulation [17]. P16INK4a binds to CDK4 and CDK6, thus inhibiting both
proteins. P14ARF binds to human double minute-2 (HDM2) protein to promote its
degradation [18]. Since HDM2 in turn ubiquitinates and condemns p53 to degradation,
the total effect of p14ARF loss is a destabilization of p53 [18, 19]. Therefore, CDKN2A
removes both the RB and p53 pathways through the loss of p16INK4a and p14ARF,
respectively [20].
As stated previously, cyclin-dependent kinase 4 (CDK4) mutations have been
found in roughly 10% of melanomas [16]. CDK4 is a cell cycle checkpoint protein, and a
mutation would lead to cell cycle progression. Mutations occur at a conserved arginine
residue, such as Arg 24, which negates the interaction with p16INK4a [17]. As shown in a
mouse model expressing mutated R24C within CDK4, there was a significant increase in
potential to acquire melanoma, which supports the notion of human melanomas having
enhanced and/or mutated CDK4 [21].
Another molecule found to be commonly mutated in families with a melanoma
background is the melanocortin-1 receptor (MC1R). MC1R regulates constitutive and
facultative pigmentation and has emerged as one of the leading moderate-risk loci for
melanoma susceptibility [22]. MC1R is a G-protein-coupled receptor that activates
adenylate cyclase in response to α-MSH binding [23, 24]. Increases in cyclic AMP
upregulates microphthalmia-associated transcription factor (MITF), which induces the
transcription of the pigment synthesis genes [23]. MITF, in turn, has mutant variants of
3

its own, such as the germline variant E318K [17]. However, the prevalence of the MITF
(E318K) alteration is significantly lower (<1%) in the general Caucasian population
compared to MC1R variants [25].
Although there are other genetic loci associated with melanoma, B-Raf protooncogene, serine, threonine kinase (BRAF) mutations are the most prevalent somatic
genetic events in human cutaneous melanoma [26]. Mutations in BRAF have been found
in about 40-70% of melanomas [27], where they are frequently detected in the tumors
occurring in the skin not chronically damaged by the sun [28]. More than 50 mutations
with the BRAF gene have been identified, but roughly 90% of these mutations are singlebase transitions at position 1799, leading to the substitution of glutamic acid for valine at
codon 600 (BrafV600E) [29]. Interestingly, this mutation is not sufficient for malignant
transformation of melanocytes on its own, and it is an early oncogenic event found also at
high frequency in benign nevi [30, 31].

Melanoma Staging and Treatment
When a malignant transformation occurs, there are hallmark changes in the
physical makeup of the melanoma tumor. These physical changes include asymmetry,
border irregularity, variation in color, an increase in diameter greater than 6 mm, and
enlargement of the lesion. Upon detection of melanoma, proper staging is required in
shaping patient treatment options. Greater than 90% of early stage, localized melanoma
is cured with excision of the tumor. However, survival is halved when the tumor is
diagnosed after lymph node involvement and less than 20% when it has reached
4

metastatic disease [32]. Classification of melanoma is based on the TNM system, which
is indicative of tumor size, nearby lymph nodes, and sites of metastasis. Early stage
tumors (Stage 0, I, & II) are measured by Breslow’s depth to determine excision margins
[32]. When melanomas have invaded nearby lymph nodes to distant sites of the body
accompanied by elevated LDH levels in the blood, it is classified as stage IV, and
generally, the prognosis is grim.
Among patients with stage IV metastatic melanoma, the median survival is about
8 months (+/- 2 months), and only about 15% of patients survive more than 5 years from
diagnosis [33]. Until recently, there were few treatments available for advanced
melanoma. These treatments include chemotherapy, high-dose radiation, IL-2
administration, and immunotherapies ipilimumab, vemurafenib, and pembrolizumab.
Chemotherapy is an accepted therapy for stage IV metastatic melanoma, and
dacarbazine is the most widely used single chemotherapeutic agent for later stages [3436]. Current studies have shown response rates for dacarbazine at 5-12% [37, 38]. Most
responses are transient, and only 1-2% of patients achieve a durable long-term response
to chemotherapy [39]. However, chemotherapy is one of the most common treatments
for late stage patients due to cost effectiveness.
Radiation therapy is a mainstay of treatment for many malignancies where direct
killing of tumor cells by radiation therapy is due to irreversible DNA damage, which
leads to the induction of cellular senescence, mitotic catastrophe, necrosis, and/or
apoptosis. [40]. For many years, melanoma was considered highly radio-resistant [41].
However, this was proven untrue through many studies starting as early as 1913 by
5

Simpson et al. (reviewed in [42]). The use of local radiotherapy only to the primary site
versus treating the local site and the lymphatic regions for cutaneous melanoma is a
function of stratifying patients into low risk versus high risk for regional recurrence based
on particular clinical and biological indicators. In later stages of melanoma, patients can
receive roughly four fractions of 8Gy at weekly intervals, or 20 fractions of 2.5Gy each,
administered daily five days per week for multiple weeks [43]. This regimen of treatment
may vary due to the location of the tumor. For example, primary mucosal melanomas of
the head and neck region have a ~30% 5-year survival rate [44]. In a retrospective study,
patients received 50-70Gy overall [44]. It has also been shown that adjuvant radiotherapy
can decrease the incidence of regional lymph node recurrence in patients with positive
regional nodes in their initial surgical specimen. However, there was no evidence of any
improvement in relapse-free or overall survival [45]. These treatments can be toxic to
patients and lead to immune adverse events as well as higher susceptibility of other
cancers later in life.
High-dose recombinant IL-2 received FDA approval for metastatic melanoma
treatment in 1998 [36]. During phase II trials, a response rate of ~16% was observed
using a single agent therapy. Only about 5% of patients experienced long-term, complete
responses with IL-2. The IL-2 antitumor activity is dependent on its ability to modulate
immune responses in the host, increasing both T and natural killer cell-mediated activities
[33]. However, it has been shown that this therapy has not improved the overall survival
in the patient population [36]. Also, IL-2 treatments produce severe toxicity as well as
immune adverse events in patients. These events include hypotension, vascular leak
6

syndrome, and cardiac dysrhythmias [33]. Therefore, it was proven that IL-2
administration did not reach its potential in activating an anti-tumor immune response.
The transfer of tumor-specific T cells (ACT) has shown some promise. The most
developed approach is based on the ex vivo selection of highly reactive, tumor-infiltrating
lymphocytes (TIL), their activation and expansion before reinfusion into the patient [46].
These patients generate high response rates, but patients must be lymphodepleted to
eliminate competition for endogenous serum cytokines [47]. This approach is both laborintensive and costly, where it may take several weeks for cell culture to acquire enough
cell numbers needed for an optimum response. Also, patients must be able to withstand
the intensity of ACT, which includes total body irradiation and IL-2.
Because of the poor results from the IL-2 clinical trials as well as other adjuvant
therapies (i.e. IFN-α, whole cell, and dendritic vaccines), different immunotherapies were
developed in order to combat metastatic melanoma. In 2011, ipilimumab and
vermurafenib received FDA approval to treat late stage melanomas.
Ipilimumab is a monoclonal antibody that targets cytotoxic T lymphocyteassociated antigen (CTLA-4), which is a co-inhibitory molecule that functions in
regulating T cell activation [48]. In phases II and III clinical trials, ipilimumab
demonstrated improved overall survival versus gp100 peptide vaccine and dacarbazine,
independently [48]. However, during phase III trials, the response rate, complete
response and partial response was only 10-15%, and the disease control rate was about
30% [48]. While ipilimumab is capable of inducing a long-term response in a minority of
patients, the low response rate and small improvement in median survival limits its
7

effectiveness.
Vemurafenib is a selective inhibitor of Braf, a serine-threonine-specific protein
kinase. [29]. It binds to the nucleotide-binding pocket of BrafV600E with higher affinity
than ATP and renders the kinase unable to phosphorylate downstream targets [33]. This
inhibition leads to cyclin D1 suppression, induction of cell cycle inhibitor p27, and
eventually cell-cycle arrest [49]. During phase III trials with untreated patients with the
BrafV600E mutation, overall survival at 6 months was 84% compared to 64% of patients
treated with dacarbazine, while the response rates were 48% and 5%, respectively [50].
In September 2014, the FDA also approved the drug pembrolizumab for late stage
melanoma as well. Pembrolizumab is a highly selective antibody against programmed
death 1 (PD-1), where early clinical trials have shown high tumor response rates and long
duration of effect in previously treated advanced melanoma [51]. Due to the new
approval for this drug, long-term effects and effectiveness of this drug have not be further
assessed.
Treatments such as ipilimumab and vemurafenib have shown profound initial
responses in subgroups of patients, but the effect is short-lived. Drug resistance
frequently appears after 6-9 months of therapy due to the development of different
mechanisms of acquired tumor drug resistance that leads to the recovery of MAPK
signaling or activation of alternative signaling pathways [33, 52]. This acquired
resistance in unresectable/metastatic melanoma patients has become an increasing
setback. A possible solution to acquired resistance is developing combination-targeted
therapies. Current studies include combining chemotherapy/radiation with ipilimumab
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and/or vermurafenib as well as other immunotherapy strategies [33, 36, 41, 53].
Biochemotherapy, such as cisplatin, vinblastine, and dacarbazine combined with
IFN-α +/- IL-2, increases response rate, but has not been shown to significantly improve
survival compared with chemotherapy alone in randomized phase II and II trials [34, 54].
Until today, biochemotherapy has not demonstrated significant clinical benefit in
adjuvant trials nor in randomized prospective studies in the metastatic setting, but it is
associated with additive toxicity [36]. Therefore, biochemotherapy regimens cannot be
regarded as standard clinical practice and should be further evaluated in clinical trials
[36].
On the other hand, bioradiotherapy strategies look to combine radiation therapy
with immunotherapy. Such studies involved examining immunotherapies interferon-α2b,
IL-2, ipilimumab, and ACT [33, 36, 46, 55-57]. In each of these studies, data suggests
that these treatments may interact and lead to increased therapeutic effects, adverse
events, or both. Interestingly, a retrospective analysis of 29 patients who received
ipilimumab with radiation, there was no significant increase in adverse effects related to
immunotherapy [56]. However, at the highest doses of administered radiation therapy, an
increase in radiation therapy-related adverse events was noted. Importantly, in these
studies, high doses of radiation are being administered to these patients. A 66 year-old
patient received ipilimumab after recurrent, metastatic melanoma. The patient received
27Gy in 3 fractions after metastasis to the right internal mammary lymph node was
detected. After three months after radiotherapy, the tumor had decreased in size from
1.5x1.6cm to 1.2x0.7cm [53]. Given the immunologic effects of radiation therapy, there
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are ongoing investigations into radiation therapy and immunotherapy in the treatment of
patients with melanoma [53]. Currently, there are two Phase I trials examining
ipilimumab with different types of radiation therapy, three Phase I/II trials, and four
Phase II trials comparing bioradiotherapy to ipilimumab alone. Therefore, a better
understanding of the mechanisms underlying bioradiotherapies is essential in optimizing
the key goal of killing malignant cells while boosting immune responses.

Inflammation and Angiogenesis in Melanoma

At the cellular level, melanoma tumors differentially express cytokines,
chemokines, and soluble molecules responsible for immunosuppression and tumor
proliferation. Inflammation is a part of the host’s response to either internal or external
environmental stimuli [58]. Melanoma cells have a strong cytokine-secreting ability and
complex cell signaling networks [59]. This cytokine-secreting ability may also have an
impact on melanoma invasion and detection. Inflammatory cytokines like IL-6, IL-12,
IL-17, and IL-23 have been observed in melanoma [60-62]. Patients with elevated levels
of IL-6 were more likely to have elevated TNFα, which allowed them to be susceptible to
relapse and toxicity [63]. IL-6 has been correlated with STAT3 activation, a
transcription factor involved in the regulation of the immune system, inflammation, cell
survival, and cell proliferation [64]. When IL-6 is induced by IL-17, this, in turn, can
stimulate the upregulation of STAT3 [61]. There have been many conflicting reports on
the study of IL-6; when in early stages, IL-6 can be beneficial to tumor clearance.
However, as the disease worsens, IL-6 can actually aid in the tumor progression. Also, an
up-regulation of IL-6, IL-8, and IL-1β cytokines were observed in fibroblasts that were
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co-cultured with highly invasive melanoma cell lines BLM and MV3 [65]. Melanomaassociated fibroblasts dominate the surrounding tissue around the tumor which suggests
that the tumor microenvironment plays an essential role in invasion and metastasis.
Another cytokine, IL-10, has been known to have immune suppressive properties. In one
study, IL-10 mRNA was compared between melanoma tumors and metastasis with
normal tissue [66]. Four out of five melanoma biopsies detected IL-10 mRNA, whereas
the normal tissues did not express detectable levels of IL-10 [66]. Also, patients with
advanced melanoma have a high percentage of CD4+ CD25HighFoxp3+, IL-10-producing
T regulatory lymphocytes [67]. The secretion of these cytokines may have the ability to
create a microenvironment that leads to toxicity and invasion.
Along with inflammation at the tumor site, angiogenesis, the process of new
formation of blood vessels from preexisting ones, may also enhance the cancer’s ability
to metastasize. Melanoma angiogenesis has been linked with poor prognosis, patient
survival, ulceration, and an increased rate of relapse [68]. While malignant melanoma
progresses, metastatic cells have to exit the primary tumor site by loosening cell to cell
contact, adhering to and degrading extracellular matrix (ECM), migrating through the
subendothelial basement membrane of local post-capillary veins and lymphatic vessels,
and intravasating [69]. Secretion of the angiogenic molecule vascular endothelial growth
factor (VEG-F) by melanoma cells has been correlated to the transition from the radial to
the vertical growth phase [70]. VEG-F regulates the permeability of the endothelial
barrier where it plays a vital role in tumor angiogenesis and is associated with most
advanced stage melanomas [71, 72]. It also has been demonstrated that the upregulation
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of VEG-F expression in metastatic melanoma is linked with an increase in the number of
tumor-infiltrating inflammatory cells expressing VEG-F [73]. It may inhibit cytotoxic
immune responses, promote tumor cell proliferation, and facilitate vascular dissemination
of melanoma cells [69].
Another angiogenic factor that has been observed in melanoma is IL-8 [65, 74].
IL-8 expression is scarcely found in normal epidermis and benign melanocytic lesions
[73]. IL-8 as well as IL-6 can act as circulating tumor cell attractants, which can
accelerate tumor growth, angiogenesis, and recruitment of other chemo-attractant
molecules [60]. IL-8 can promote nuclear translocation of STAT3 and β-catenin, without
transcriptional activity [75]. IL-8 signaling has also been shown to increase the
transcription of nuclear factor-κB (NF-κB) in melanoma, which may be increased
through protein kinase C (PKC) activity [76]. Along with NF- κB, STAT3, and β-catenin,
IL-8 indirectly upregulates the activity of AP-1 and mTOR, which are both implicated in
cell proliferation, invasion, and cell survival [77]. VEG-F is linked with IL-8 signaling
through its activation by the GPCR of the IL-8 receptor. It has also been demonstrated
that transforming growth factor-1 (TGF-1) has the ability to enhance IL-8 expression in
human melanoma cells and promote angiogenesis in multiple xenograft models [78].
Other angiogenic factors involved in melanoma include, but are not limited to, the
matrix metalloproteinases (MMPs). MMPs are a large group of secreted proteinases that
are involved in normal physiological and pathologic processes such as embryogenesis,
wound healing, angiogenesis, tissue remodeling, tumor invasion, and metastasis [79].
Within this family of proteins, MMP-2, MMP-9, MMP-13, and MMP-14 have been
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observed in melanoma and are used as biomarkers for staging [80, 81]. MMP-2 and
MMP-9 degrade connective tissue and basement membrane collagen and are believed to
play an important role in skin and uveal melanoma progression [79, 82]. The expression
and activation of both enzymes have been correlated to the invasive and metastatic
phenotypes of the tumors [73]. More so, MMP-2 expression contributes to metastatic
spread and low survival rates [83]. MMP-9 has been found during the radial growth
phase, but not the vertical phase, which suggests that MMP-9 is utilized during early
events in melanoma progression [84]. An upregulation of these proteins may create a
microenvironment that promotes melanoma invasion, metastasis, and evasion of the
immune system. These inflammatory cytokines and angiogenic factors can play a vital
role in the aggressiveness of melanoma, and they may also aid in the immune evasion of
these cells. Understanding the regulation of melanoma cells by the immune system may
help in the targeting of inflammatory and angiogenic molecules, thus shifting the tumor
microenvironment to an anti-tumor state.

Melanoma and the Immune System
Melanoma is characterized as one of the most immunogenic tumors due to the
presence of tumor-infiltrating lymphocytes in resected melanoma, some regressions, and
clinical responses to immune activation [48]. The multiple ways that melanoma alters the
immune system locally, at the site of the tumor, and systemically makes the disease
difficult to treat, but ideal for the study of immunomodulation [85]. Immunomodulation,
the alteration of the immune system or its function, is exploited in multiple forms by
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melanoma tumors from changes in the cellular and sub-cellular makeup of the tumor to
changes in the tumor microenvironment that suppress localized and systemic attempts at
disease reduction. Therefore, many studies investigated mechanisms leading to tumor
immune evasion.
Establishing a permanent immunological memory is an ideal strategy for current
immunotherapies while providing an immune attack upon malignancies. Long-lasting
immune responses and protection against melanoma is mainly dependent upon the
activation of CD8+ and CD4+ T cells via the HLA class I and II pathways [86]. The
HLA class II pathway is a critical component of the immune system as they present both
self and foreign peptides to CD4+ T cells [87]. Through this pathway, a robust and
lasting immune response can be generated as well as the establishment of effective
immune memory [88]. HLA class II alpha/beta heterodimers are synthesized within the
endoplasmic reticulum (ER) of cells and form a complex with the glycoprotein invariant
chain (Ii) [89-91]. In the endolysosomal compartments, acidic proteases such as
cathepsins S and L begin to degrade Ii into smaller intermediate peptides, leaving the
class II-associated Ii peptide (CLIP) in the class II binding groove [92-95].
Simultaneously, processing of antigens (Ags) is occurring by acidic cathepsins B and D
[92, 96, 97]. These acidic proteases unfold, cut, and splice both exogenous and
endogenous Ags into smaller peptides. The non-classical class II molecule, HLA-DM,
chaperones the removal of CLIP from the peptide binding groove and catalyzes the
loading of high affinity peptides, leading to a stable HLA class II-peptide complex [88,
98, 99]. This complex is then transported to the cell surface for CD4+ T cell recognition.
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Recent studies have shown that melanoma cells can constitutively express class I and
class II proteins [100]. It has previously been reported that melanoma cells expressing
HLA class II molecules cannot process cysteinylated peptides, leading to immune evasion
[101, 102].
Melanoma cells lack an enzyme that is required for proper Ag processing and
presentation to CD4+ T cells. Spontaneous cysteinylation of peptides and antigens
occurs to interrupt HLA class II presentation [103]. This cysteinylation occurs through
the formation disulfide bonds between cysteine residues or when cysteine residues bind
to free-floating cysteine in the cytosol [101]. Gamma Interferon-inducible Lysosomal
Thiol reductase (GILT), is an enzyme that can restore T cell recognition of cysteinylated
melanoma tumor antigens [101]. GILT is abundantly expressed in professional antigen
presenting cells (APCs), but is absent or very low in melanoma [104]. Within APCs,
GILT is found in its proforms in early endosomes while its mature form is found in
multivesicular late endosomes and multilaminar lysosomes [105, 106]. GILT is
synthesized as a precursor and targeted via the mannose-6 phosphate receptor to the
endolytic pathway where N- and C-terminal propeptides are removed to generate the
mature form at 30 kDa [107]. GILT is active at a low pH and catalyzes the breaking of
disulfide bonds, allowing Ags to unfold, which allows antigens and peptides to be further
processed by acidic cathepsins as shown in Figure 1.1.
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Figure 1.1 The role of GILT in the breaking of disulfide bonds. (A) GILT is
active at low pH and catalyzes the breaking of disulfide bonds, making
Ags/peptides unfold and can be further processed by acidic cathepsins. (B)
Cysteine-containing processed peptides may become susceptible to disulfide bond
formation with free-floating cystine in the cytosol, allowing the peptide to become
oxidized (non-functional). Again, in the presence of GILT, the bond is broken, the
peptide is reduced or functional, and can be efficiently loaded onto HLA class II
molecules.
It has studied that GILT can be induced in melanoma by treatment with IFN-γ
[97]. We have previously shown that GILT expression in melanoma cells increased
HLA-DM molecules, favoring epitope loading onto class II molecules [97]. We also
reported that GILT can upregulate active forms of cysteinyl cathepsins B and S as well as
aspartyl cathepsin D [97]. Further investigation led to the finding that GILT colocalizes
with cathepsins B and D in the endosomal/lysosomal compartments, leading to increased
Ag processing and presentation [97].
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Previous studies suggest that GILT is necessary for processing of posttranslationally modified/oxidized epitopes for HLA class II-mediated presentation [108].
We have previously shown that GILT is regulated by signal transducers and activators of
transcription 1 (STAT1) and not by the previously believed class II transactivator
(CIITA), which is imperative for the activation of HLA class II gene loci [109]. GILT
expression has been shown to enhance processing of Ags and peptides and CD4+ T cell
recognition [101, 108]. An alteration in the expression of tumor Ags or disturbance in
HLA class II presentation may be the reason why tumors cells evade immunogenic
ablation [110-112]. Thus, the restoration of the HLA class II-peptide presentation
pathway in melanoma may help tumor cells promote immunological destruction [86].
However, the mechanism that GILT utilizes in class II Ag presentation has yet to be
clearly defined.

Significance
Melanoma is the 5th most common cancer in the United States [1]. Improved
treatment options are necessary to combat this disease. Immunotherapies have had some
success at fighting this disease at the earliest stages, but fail with aggressive, metastatic
melanoma. Also, most of these treatments can be extremely toxic and harmful to
patients. Alternative treatments must be sought out to fight this deadly disease. As
previously stated, the insertion of GILT is vital for proper HLA class II antigen
processing and presentation in melanoma [101, 108].

Current treatments for metastatic

melanoma include surgery, chemotherapy, high-dose radiation, and some
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immunotherapies. However, these treatments appear futile once the tumor has
metastasized beyond localized lymph nodes. This stresses the need for improved disease
targeting as well as new possibilities for combining treatments. Three parts of this study
intend to investigate how GILT expression generates a greater pool of antigenic peptides
for HLA class II-mediated presentation by human melanoma cells, how GILT negatively
regulates the tumorigenic molecule PAX3 in human melanoma cells, and the modulation
of GILT and PAX3 enhances radiation and chemoimmunotherapy of melanoma. Thus,
current therapies may be optimized in combination with targeting PAX3 to enhance
melanoma cell death.
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Chapter 2: GILT expression generates a greater pool of reduced peptides for HLA
class II-mediated presentation by human melanoma cells.

Introduction
As previously mentioned, melanoma is one of the most rapidly growing cancers
plaguing western populations [1, 2]. To fill the gap in treatment options, immunotherapy
has been tried in multiple forms over the past decade. Of these, autologous T cell transfer,
interferon therapy, whole cell cancer vaccines, and antibody therapy (e.g., Ipilimumab
and pembrolizumab) have had some success, yet an effective immunotherapy remains
elusive. One of the main failures associated with melanoma immunotherapy is an
incomplete stimulation of both CD4+ and CD8+ T cells [113-115], leading to incomplete
tumor clearance and no gaining of effective immunological memory. This chapter looks
to dissect novel Ag processing reactions in melanoma that could be exploited in both
loaded dendritic cell and melanoma whole cell vaccine strategies.
The most widely known melanoma Ags are MART-1, NY-ESO-1, gp100, and
tyrosinase [116-122]. These Ags have been shown to elicit both cytotoxic CD8+ and
helper CD4+ T cell responses [123]. It is believed that cancer cells are mainly eliminated
as a result of stimulation of by both natural killer and CD8+ T cells [124]. While
cytotoxic CD8+ T cells are able to destroy melanoma cells [125-127], their interaction
with tumor cells and killing efficiency are greatly supported in combination by CD4+
helper T cells [113]. One of the immune evasion mechanisms could be the oxidation of
Ags/peptides that leads to posttranslational modification, masking tumor cells from T
cell-induced cell death. Melanoma Ags MART-1, NY-ESO-1, gp100, and tyrosinase all
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contain multiple epitope sequences specific for class II binding, many of which contain
cysteine residues, which may also perturb CD4+ T cell recognition of melanoma cells
[116, 120, 121, 128]. However, it remains unknown whether the expression of GILT in
melanoma cells could enhance processing of these cysteinylated Ags/peptides to produce
a greater pool of functional epitopes for delivery to CD4+ T cells via the HLA class II
pathway.
In the previous chapter, it was stated that GILT is abundantly expressed in APCs,
but is absent or very low in melanoma as well as other tumors [129]. GILT expression
can be induced in melanoma and other tumor cells by treatment with IFN-γ [130]. GILT
is active at low pH and catalyzes the breaking of disulfide bonds, making Ags/peptides
susceptible to degradation by acidic cathepsins. Recent evidence suggests that GILT
plays a role in the processing of post-translationally modified epitopes for HLA class IImediated presentation to T cells [108]. The HLA class II pathway is a critical component
of the immune system as it is responsible for presenting both self and foreign peptides to
CD4+ T cells [87]. Once peptides are loaded onto HLA class II molecules, the T cell
receptor (TcR) interacts with the HLA class II-peptide complex, and members of the B7
family (CD80/CD86) interact with CD28 molecules on the T cell surface [131, 132].
Through this pathway, a robust and lasting immune response can be generated as well as
the establishment of effective immune memory [88].
An alteration in the expression of tumor Ags or disturbance in the HLA
presentation pathway may be the reason why tumor cells evade immunogenic ablation
[110-112]. Thus, the restoration of the HLA class II peptide presentation pathway in
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melanoma may help tumor cells to promote immune-mediated destruction [86]. However,
a complete understanding of GILT’s involvement within the class II pathway has yet to
be determined, and may contribute to the regulation of other factors, such as
costimulatory molecules and intracellular proteases. Cathepsins B, D, S and L are
lysosomal proteases found in professional APCs as well as in tumors [133-136].
Modulation of cathepsin expression and activity could likely lead to differential Ag
processing and altered peptide repertoire in GILT-positive melanoma cells.

Hypothesis
I tested the hypothesis that GILT expression enhances cathepsin expression and
activity in melanoma cells, leading to a greater generation of antigenic peptides for HLA
class II-mediated presentation and CD4+ T cell recognition of melanoma.

Research Strategy
Experiment 1: Generated GILT-expressing melanoma cell lines.
Experiment 2: Tested HLA class II components (HLA-DR, HLA-DM, Ii, etc.) for
protein expression in GILT +/- human melanoma cell lines.
Experiment 3: Examined costimulatory molecules (CD80, CD86) in GILT +/human melanoma cell lines.
Experiment 4: Investigated aspartyl and cysteinyl cathepsin expression and
activity in GILT +/- human melanoma cell lines.
Experiment 5: Analyzed peptide generation from supernatants collected from
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GILT +/- human melanoma cell lines.

Materials & Methods
Cell lines
Human melanoma cell lines DM-331(University of Virginia) and HT-144 were
grown in complete RPMI-1640 (Invitrogen, Grand Island, NY) medium containing 10%
fetal bovine serum (FBS) (HyClone, Logan, UT), 50 U/ml penicillin, 50 µg/ml
streptomycin (Mediatech Inc., Manassas, VA), and enriched with 1% L-glutamate
(Mediatech) [109]. The human melanoma cell line J3 was cultured in complete IMDM
media containing 10% bovine growth serum (BGS) (HyClone), 50 U/ml penicillin, 50
µg/ml streptomycin (Mediatech), and enriched with 1% L-glutamate (Mediatech) [101].
A human B-lymphoblastic cell line Frev (Dr. Janice Blum, University of Indiana) was
also used as a positive control for GILT expression to test melanoma cell lines. Frev cells
were cultured in suspension in complete IMDM media (CellGro) containing 10% BGS
(HyClone), 50 U/ml penicillin, 50 µg/ml streptomycin (Mediatech), and enriched with
1% L-glutamate (Mediatech). The T cell hybridoma cell line 2.18a, specific for κ188-203
peptide, was cultured in complete RPMI-1640 with 10% FBS, 50 U/ml penicillin, 50
µg/ml streptomycin, 1% L-glutamate, and 50μM β-mercaptoethanol (β-ME) [101, 137].
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Table 2.1 Cell lines utilized for chapter 2.
Melanoma Cell Line

Conditions/Treatments

Reason for use

J3.DR4

+/- GILT

DM-331

+/- GILT

Retrovirally transduced to express
DR4, to determine role of GILT in
Ag processing and presentation
Constitutive expression of DR4, to
determine the role of GILT in Ag
processing and presentation

DNA transfection assays
The human melanoma J3 cells were transduced using retroviral vectors for
constitutive expression of HLA-DR4 (DRB1*0401) with linked drug selection markers
for puromycin and histidinol resistance [101]. Surface HLA-DR4 complex expression on
cells were confirmed by flow cytometric analysis using the DR4-specific mAb, 359-F10
[138]. Human melanoma cell lines DM-331 and HT-144, which constitutively express
HLA-DR4 molecules on the cell surface, and J3.DR4 were transfected with a plasmid
encoded with GILT cDNA and a puromycin drug resistance gene or a vector-encoded
plasmid with the same puromycin drug resistance gene using a lipofectamine transfection
reagent (Sigma-Aldrich, St. Louis, MO). All melanoma cell lines were first grown in
100mm tissue culture plates, incubated at 37oC with 5% CO2 until each plate reached 7080% growth confluence. Cell growth media was then aspirated and each plate was
washed twice with DPBS (HyClone). Cells were then removed from the culture plate
using Trypsin EDTA (Invitrogen), collected and counted. Cell volumes were adjusted to
1x106 cells per ml. Next, 1ml of cells were added to each well of a 6 well tissue culture
late (Corning Incorporated). Each cell line was allowed time to adhere before
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transfection began, under non-supplemented RPMI culture conditions. During which
time a DNA lipofectamine complex was made. The DNA/lipofectamine complex
consisted of 5 µg/µl of cDNA, either vector or GILT extracted plasmid cDNA, in 22 µl of
lipofectamine reagent brought to a final volume of 600 µl in serum free RPMI media.
This mixture was incubated for 30 minutes prior to being added to the cells. After the
incubation time, 2.4 ml of serum free RPMI was added to the DNA/lipofectamine
complex mixture and 1 ml of the mixture was added to each well of the 6 well culture
plate containing the melanoma cells, 3 wells received the vector cDNA complex, and 3
wells received the GILT cDNA complex. These cells were then incubated under normal
cell culture conditions for 24 hours then transfected cells were selected and expanded
based upon encoded drug resistance to puromycin dihydrochloride (Sigma-Aldrich, St.
Louis, MO). GILT expression was then assessed through western blot analysis.

Preparation of cell lysates
Transfected cells were grown to 80% confluence on 100mm plates, and then
removed from the culture plate using Trypsin EDTA (Invitrogen), and collected in 15ml
conical tubes. Cells were washed twice with HBSS (HyClone) and frozen at -80oC for 24
hours. These pellets were next lysed in a complete lysis buffer composed of 10mM Tris,
pH 7.5, 150 mM NaCl, 1% Triton X-100, 100 µM tosyl-Lys-chloromethyl ketone, and
200 µM PMSF on ice. Lysates were centrifuged at 2000 rpm for 5 minutes at 4oC to
remove cell nuclei and major cell debris. The supernatant from this was then transferred
to a new centrifuge tube and re-centrifuged at 10,000 rpm for 8.5 minutes to ensure that
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only protein was collected. The protein concentration within these cell lysates was
determined using an albumin standard (Thermo Scientific) and all cell lysates were stored
at -20oC until future use in western blot analysis.

Protein determination
Cell lysates were assessed for protein concentration using a 2.0 mg/ml Bovine
Serum Albumin standard (Thermo Scientific). Control albumin was diluted at limiting
concentration values of 1, 0.8, 0.6, 0.4, 0.2, and 0µg/µl and loaded into an EIA medium
binding 96 well plate (Corning Incorporated) in triplicate. Cell lysates were then added
to test wells containing 20 µl of DDH2O in triplicate. All wells then had 25 µl of BioRad
working solution A (20 µl of BioRad DC Protein Assay reagent S in 1ml of BioRad DC
Protein Assay reagent A) followed by the addition of 200 µl of BioRad DC Protein Assay
reagent B, and allowed this to incubate at room temperature for 15 minutes. Plates were
read at 630 nm using a BioTek ELx800 absorbance reader (BioTek). A line of best fit
was determined based on the BSA standard, the equation of which was used to determine
the amount of protein in µg/µl of each test sample.

Western blotting and densitometry
Once protein levels were quantified following cell lysate and protein
determination, equal amounts of protein from vector and GILT matched cell lines were
subjected to the reduced and boiled technique. All samples that were reduced had 1.5 µl
of DTT reducing agent added to the sample protein with a standard amount of loading
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buffer (NuPage Sample Buffer). All samples that were boiled after appropriate amounts
of protein sample, loading buffer, and complete lysis buffer (to equilibrate reaction
volumes) have been added, were heated on a heat block at 70oC for 10 minutes. After
these steps concluded, the samples were loaded onto NuPAGE 4-12% Bis-Tris gels
(Invitrogen) and run at 200 volts for 50 minutes. Bis-Tris gels containing protein were
then transferred to nitrocellulose membranes (Osmonics) employing a transfer chamber
subjected to 30 volts for one hour. Nitrocellulose membranes were then removed and
blocked in a solution of 5% milk in Tris-Buffered Saline and Tween 20 (TBS-T)
overnight at 4oC. After incubation, the nitrocellulose membranes were probed with
protein specific mAbs. A β-actin antibody (Santa Cruz) was used as an equal protein
loading control. Probed nitrocellulose membranes were next assessed using
autoradiography film, following incubation with 3ml of Luminata Crescendo Western
HRP Substrate (Millipore Corporation, Billerica, MA) for 3 minutes. Autoradiography
films were scanned using a Canon MP250 scanner/printer and analyzed using a BioRad
Geldoc XRS photocenter, where densitometric software enabled for the quantification of
protein densities, based against respective actin controls.

Ags, peptides, and antibodies
The whole Igκ was purchased from Sigma-Aldrich. The human IgG
immunodominant peptide κ188-203 (sequence KHKVYACEVTHQGLSS) was produced by
Fmoc technology and Applied Biosystems Synthesizer [103, 137]. Peptide purity (>99%)
and sequence were analyzed by reverse phase HPLC purification and mass spectroscopy.
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Nitrocellulose membranes were subjected to probing with various antibodies. The
antibodies used were human GILT, HLA-DM, CD80, CD86, Cat B, Cat D, Cat S, Cat L,
and β-actin (Santa Cruz Biotechnology Inc., Santa Cruz, CA). HLA-DR (L243) and Ii
(Pin 1.1) were obtained from Dr. Janice Blum, Indiana University School of Medicine,
Indianapolis, IN. Nitrocellulose membranes were incubated for 2-3 hours, rolling, at
room temperature with a given antibody at a predetermined concentration (as per
manufacturer standard) in a solution of 2.5% milk in TBS-T. Following incubation time,
blots were washed for 30 minutes in TBS-T before being probed with the horseradish
peroxidase secondary antibodies conjugated for anti-mouse (Pierce, Rockford, IL), antirabbit or anti-goat (Santa Cruz) for one hour. Finally, blots were washed again in TBS-T
for 30 minutes then subjected to Luminata Crescendo Western HRP Substrate (Millipore
Corporation, Billerica, MA) and assessed as described in western blot methods.

Confocal microscopy
J3.DR4.vec and J3.DR4.GILT cells were grown to 80% confluence to then be
transferred to a 6 well plate with one coverslip (sterilized in 70% ethanol) with 5.0 x 105
cells in each well. After the cells had adhered for 24 hours, cells were washed with 1ml
paraformaldehyde at room temperature for 20 minutes. Cells were then washed with 1ml
of PBS/0.01% Triton-X/0.01% Glycine at room temperature for 15 minutes on the shaker
twice. Next 500 µl of 5% BSA/PBS was added to each well and incubated at room
temperature for 10 minutes. Coverslips were transferred to a labeled slide. 100 µl of 5%
normal serum (50 µl/1ml 1% BSA/PBS) was added to each slide and incubated for 10
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minutes at room temperature followed by 50 µl of primary antibody diluted in 1%
BSA/PBS added directly over the coverslip and incubated for 1 hour. Slides were
washed in 1% BSA/PBS (200µl per slide) on the shaker for 10 minutes twice. Next, 50100 µl of 5% normal serum was added to each slide and incubated at room temperature
for 10 minutes. Slides were dried using a paper towel and 50 µl of secondary antibody
was added and incubated in the dark at room temperature for 1 hour. All steps following
were performed in the dark at room temperature. Secondary antibody was removed and
200 µl of 1% BSA/PBS was added for 10 minutes on the shaker twice. Liquid was
removed and 200 µl of PBS was added, placed on the shaker for 5 minutes twice. 60 µl of
DAPI stain was added to the slides for 10 minutes at 1:5000 dilution in 1% BSA/PBS.
Liquid was removed, and slides were washed twice with PBS for 10 minutes each. A
new set of slides were labeled and 20 µl of Fluoromount-G mounting media was added to
each slide. Old slides were completely dried, and the coverslips were transferred to new
slides and incubated for 1 hour. Slides were dried and nail polish was added to the outer
edges of the coverslip and left overnight. Images were taken the following day using a
Leica TCS SP2 AOBS, 63 water immersion objective using 405 and 543 lasers. Images
with each staining were taken using the overlay to assess the positioning of the protein in
question.

Flow cytometry
J3.DR4.vec, J3.DR4.GILT, DM-331.vec, and DM-331.GILT cells were cultured
and washed with staining buffer (PBS+1% heat-inactivated BGS) (Hyclone), and
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resuspended in a binding buffer (cat. No. 556454, BD Bioscience: 0.1 M HEPES (pH
7.4), 1.4 M NaCl2, and 25 mM CaCl2). Next, 5x105 cells were stained and incubated
with 2µl of primary antibody for 1 hour at 4oC with anti-DR, anti-CD80, and anti-CD86
(Santa Cruz). Cells were then washed with isotonic phosphate-buffered saline with
5%fetal calf serum 4 times. Cells were then incubated with 1ul of fluorescence labeled
secondary antibodies for 1 hour. Cells underwent additional wash steps with isotonic
phosphate-buffered saline with 5% fetal calf serum 4 times. Cells were then fixed with
2% paraformaldehyde. Samples were then analyzed on a FACScan using CellQuest
software (BD Bioscience, Mountain View, CA) for cell surface expression of class II,
CD80/CD86 molecules with NN4 and other appropriate isotype controls [97, 139, 140].
Data presented is representative of three independent experiments.

Cathepsin Bioassay
Cathepsin B, S, L, and D activity assay kits were purchased from BioVision, Inc.
(BioVision). Cathepsin B, S, L, and D activity was measured in human melanoma cells
J3.DR4.vec, J3.DR4.GILT, DM-331.vec, and DM-331.GILT. Cells were collected in cell
line appropriate media by centrifugation at 1x106ml, where cells were lysed in 50ul of
chilled CB Cell Lysis Buffer (BioVision). Cells were incubated with CB Cell Lysis
Buffer for 10 minutes, centrifuged at 10,000rpm for 5 minutes, and supernatants were
transferred to a new tube. 50ul of cell lysate was added in triplicate to a 96-well plate.
50ul of CB Reaction Buffer (BioVision) was added to each sample, and 2ul of the 10mM
CB Substrate Ac-RR-AFC (200uM final concentration (BioVision) was added. The CB
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Inhibitor provided in the bioassay was used as a negative control. Plates were incubated
at 37oC for 1-2 hours. Plates were read at 400nm excitation filter and 505nm emission
filter using a BioTek ELx800 reader (BioTek). Experiments were performed in triplicates
and repeated at least three times. Results and standard deviations for a single
representative experiment were shown.

Liquid chromatography-mass spectroscopy (LC-MS)
J3.DR4.vec and J3.DR4.GILT were cultured, fed with IgG κ for 24 hours.
Supernatant was then collected, and the κI peptide KHKVYACEVTHQGLSS was
analyzed by capillary liquid chromatography using an Applied Biosystems 140D solvent
delivery system. Samples were applied directly to 300μM diameter fused silica
capillaries packed with Vydac C18 resin and separated with gradients of buffer A (2%
acetonitrile and 98% H2O containing 0.2% isopropanol, 0.1% acetic acid and 0.001%
trifluoroacetic acid) and buffer B (95% acetonitrile and 5% H2O containing 0.2%
isopropanol, 0.1% acetic acid, and 0.001% trifluoroacetic acid). Peptide was eluted at a
flow rate of 7μl/minute directly into the electrospray ionization source of a Finnigan LCQ
mass spectrometer. Nitrogen was used as the sheath gas with a pressure of 35 psi with no
auxiliary gas. Electrospray ionization was conducted with a spray voltage of 4.8 kV, a
capillary voltage of 26V, and a capillary temperature of 200oC. Spectra were scanned
over an m/z range of 200-2000. Base peak ions were trapped using the quadruple ion trap
and further analyzed with a high resolution scan (zoom-scan) using an isolation width of
3 m/z and collision-induced dissociation scans with a collision energy of 40.0.
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Sample Preparation for LC MS/MS
Cell elutions were reduced with DTT and alkylated with 55mM iodoacetamide.
The protein was digested with 100ng of trypsin (Sigma, proteomics grade) overnight at
37oC. The digested sample was then desalted using a C18 ziptip (Milipore) following the
manufacturer’s protocol. The eluent was dried down, and peptides were resuspended in
5μL of mobile phase A (98% water, 2% acetonitrile, 0.1% formic acid) and transferred to
an auto sampler vial for LC-MS/MS analysis.

LC MS/MS Analysis-LTQ XL
Trypsin-digested samples were analyzed via liquid chromatography (LC)electrospray ionization (ESI)-tandem mass spectrometry (MS/MS) on a linear ion trap
mass spectrometer (LTQ, Thermo) coupled to a Dionex U3000 nano LC system. A 25cm
75micron C-18 reversed phase LC column (packed in house, with Waters ODS C18, 5u)
was utilized with a 120 minute gradient from 2%acetonitrile, 0.2% formic acid to 50%
acetonitrile, 0.2% formic acid. Data Dependent Analysis was utilized on the LTQ to
perform MS/MS on the 10 most intense ions in each MS spectra with a minimum ion
count of 1000.

Database Searching and Quantitation
The raw data were searched with Proteome Discoverer 1.4. The Human IPI v3.72
database was used. Static modification of carbomidomethyl on cysteines and variable
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modifications of methionine oxidation and the oxidation, di-oxidation, tri-oxidation, and
cysteinylation of cysteines were included. Protein identifications must have 2 unique
peptides with an Xcorr vs. charge state > 1.5, 2.0, 2.5 for +1, +2, and +3 ions, a good
match for at least 4 consecutive y or b ion series from the MS/MS spectra to be
considered a positive identification. Peptides identified from the above analysis that were
detected in both the oxidized and reduced states were analyzed further for changes in
oxidation with treatment by GILT. Xcalibur (Thermo) was used to display the extracted
ion chromatograph (XIC) and integrate the area of the peak. Peak areas were used to
calculate the percent oxidation by dividing the summed areas for all forms of a given
peptide in its oxidized form by the summed areas for all forms of the peptide (both
reduced and oxidized) to calculate the percent oxidation. Areas from peptides with
miscleavages and those detected in multiple charge states were included in the areas. A
comparison of the percent oxidation between GILT-positive and GILT-negative samples
was then performed.

HLA class II Ag presentation assays
J3.DR4.vec, J3.DR4.GILT, DM-331.vec, and DM-331.GILT (5x105 cells/ml)
were cultured at 37oC in culture media in a 96-well plate (cat#3595, Corning
Incorporated). Whole Igκ Ag (10μM) was added to the appropriate wells and incubated
overnight. Cells were then washed and co-cultured with the κ188-203 peptide specific T
cell hybridoma (2.18a) for 24 hours. Following incubation, the plates were stored at 80oC until tested for IL-2 production. Cells +/- GILT were also incubated with whole
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IgGκ overnight at 37oC. Supernatants were collected by centrifugation, filtered with a
0.45 μM filter and incubated with J3.DR4.vec and DM-331.vec cells overnight.
Supernatants obtained from GILT-expressing cells were also incubated in the presence of
oxidized cysteine (290 μM), which were incubated with cells that were then fixed in 1%
paraformaldehyde, washed and co-cultured with the κ188-203 peptide specific T cell
hybridoma (2.18a) for 24 hours. T cell production of IL-2 was measured by enzymelinked immunosorbent assay (ELISA) according to the manufacturer’s instructions (R&D
Systems, Minneapolis, MN, USA) [101]. Anti-IL-2 was purchased from Sigma-Aldrich.
All assays were repeated at least three times.

Statistical Analysis
Data from each experimental group were subjected to statistical analysis.
ANOVA with post-hoc tests, Repeated Measures ANOVA with post-hoc tests, or
Student’s t-tests were used, as appropriate. Two-sided tests were used in all cases and P
values <0.05 were considered statistically significant.

Results
GILT expression influences Ii and HLA-DM protein expression in human melanoma
cells.
Studies performed in our laboratory and by others have shown that unlike many
other cancers, melanoma cells express detectable levels of HLA class II Ag-presenting
molecules [97]. Although having Ag presentation machinery, melanoma cells
inefficiently process and present Ags to CD4+ T cells, resulting in their immune
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avoidance. The reductive cleavage of protein Ags/peptides in acidic endolysosomal
compartments is also required before antigenic components of the class II pathway, such
as Ii and HLA-DM, can regulate epitope/peptide loading into the HLA class II binding
groove [88, 98, 99]. Ii regulates HLA class II presentation while HLA-DM affects
peptide loading onto class II molecules and presentation of stable class II-peptide
complexes to T cells [92]. While melanoma cells express both Ii and HLA-DM, what
remains unknown is the impact that enhanced processing of Ags by GILT will have on
the T cell recognition of melanoma cells. To examine GILT’s effect, it was first required
to express GILT in multiple human melanoma cell lines as melanoma tumors lack or
express low levels of GILT protein. Using vector/GILT cDNA and a lipofectamine
transfection reagent [97], we successfully generated melanoma cell lines J3.vec, J3.GILT,
DM-331.vec, and DM-331.GILT. Steady state GILT expression in transfected cells was
confirmed by western blot analysis, seen in Figure 2.1.

Figure 2.1. GILT insertion in human melanoma cells. Melanoma cells J3.DR4, HT-144, and DM331 were cultured and transfected with GILT cDNA or empty vector using lipofectamine transfection
assay. Cells were then cultured, lysed, and subjected to western blot analysis to test for GILT
expression. Cell lines J3.DR4.GILT, HT-144.GILT, and DM-331.GILT show high levels of GILT
protein while vector cell lines did not.

J3.vec and J3.GILT cells were further transfected with HLA-DR to generate J3.DR4.vec

34

and J3.DR4.GILT as described in the Materials and Methods section of this chapter.
Following transfection, I first examined the expression of class II proteins by western blot
analysis and flow cytometry. Expression of GILT in melanoma cells did not significantly
alter intracellular class II proteins as determined by Figure 2.2. I next examined GILT’s
effect on Ii and HLA-DM protein expression by western blot analysis. GILT expression
slightly upregulated Ii and DM proteins in two different melanoma cell lines (Figure 2.2),
which may influence the loading of Ag peptides into the class II binding groove, an
important step in Ag presentation and T cell recognition.
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(B)

J3.DR4. J3.DR4. DM-331. DM-331.
vec
GILT
vec
GILT

J3.DR4.vec
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HLADR
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-actin

DM-331.GILT
ns
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-actin

*p<0.05
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Figure 2.2 GILT insertion influences the expression of components involved in the class II pathway in human
melanoma cells. (A) Western blot analysis of whole cell lysates from J3.DR4.vec, J3.DR4.GILT, DM-331.vec and
DM-331.GILT cells showing protein expression of GILT, HLA-DR, Ii, and HLA-DM. β-actin was utilized as a loading
control. (B) Densitometric analysis was performed using β-actin as a reference protein band to quantitate relative
protein expression. Data are representative of at least three separate experiments. Significant differences were
calculated by student’s t test; *p<0.05, ns=not significant.

Flow cytometric analysis confirmed that GILT expression did not influence cell surface
expression of class II proteins (MFI: 245.06 vs. 254.16 in J3.DR4.vec and J3.DR4.GILT;
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MFI: 181.62 vs. 183.60 in DM-331.vec and DM-331.GILT) in melanoma cells (Figure
2.3). Flow cytometric analysis also confirmed that J3.DR4.vec and J3.DR4.GILT cells
expressed cell surface DR4 molecules, and the expression levels were not significantly
altered by GILT, Figure 2.4. These data suggest that GILT expression does not alter HLA
class II proteins, but may influence other components of the class II pathway in
melanoma cells, contributing to enhanced immune recognition of melanoma.
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Figure 2.3 GILT expression did not alter cell surface HLA
class II protein expression in melanoma cells. Flow
cytometric analysis of HLA class II DR molecules.
J3.DR4.vec, J3.DR4.GILT, DM-331.vec, and DM-331.GILT
cells were stained with antibody against HLA-DR (mAb
L243) for cell surface expression of HLA-DR molecules.
NN4 was used as an isotype control. The B-cell line Frev
which constitutively express HLA-DR molecules was used
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as a positive control. Data are representative
of three separate
experiments.
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Figure 2.4 GILT expression did not alter cell surface HLA-DR4 expression in melanoma cells. Flow
cytometric analysis of HLA class II DR4 molecules. J3.DR4.vec, J3.DR4.GILT, DM-331.vec, and DM331.GILT cells were stained with antibody against HLA-DR4 (359-F10) for cell surface expression of HLADR4 molecules. IN-1 antibody was used as an isotype control. Data are representative of three separate
experiments.

GILT expression upregulates intracellular CD80/CD86 molecules in melanoma cells.
A contributing component to the lack of optimal CD4+ T cell activation is the
absence or low levels of CD80 and CD86 molecules on melanoma cells [141]. A central
goal of improved melanoma immunotherapeutic design is an enhanced immune response
that includes the activation of both the cytotoxic CD8+ T cells and the supportive CD4+
helper T cells. Along with Ag presentation by HLA class II molecules on the surface of
melanoma cells, the secondary signal received by T cells plays a key role in enhancing
and prolonging the activation of CD4+ T cells. The secondary signal may come from the
interaction between CD86 and CD28 molecules as melanoma cells do not express
detectable CD40 molecules [142, 143]. However, the majority of human melanoma cells
do not express detectable cell surface CD80/CD86 molecules, and thus, they may not
provide sufficient costimulatory signals for T cell recognition. The expression of CD86
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may be turned on and/or enhanced through IFN-γ stimulation following signaling via the
JAK/STAT pathway, particularly through STAT1. Given GILT’s IFN-γ inducible nature,
our laboratory has demonstrated that GILT is indeed regulated by STAT1 [109].
J3.DR4.vec and J3.DR4.GILT melanoma cells were stained with anti-CD80, anti-CD86,
and fluorescence-labeled secondary antibody and analyzed by confocal microscopy.
These data suggest that GILT expression slight elevates CD80 while it markedly
upregulates CD86 in J3.DR4.GILT cells, seen in Figure 2.5.
DAPI

CD80

CD80+DAPI

DAPI

CD86

CD86+DAPI

J3.DR4.
vec

J3.DR4.
GILT

Figure 2.5 GILT-positive cells express higher levels of costimulatory molecules CD80 and CD86.
J3.DR4 cells transfected with empty vector or GILT were simultaneously stained with primary antibodies
against CD80 and CD86 proteins, followed by Alexa488-labeled secondary antibody as described in the
methods. Slides were analyzed by Leica TCS SP5 confocal laser scanning microscope using Las-AF
software. Representative confocal microscopy images of J3.DR4.vec and J3.DR4.GILT cells indicate
increased levels of CD80 and CD86 expression (green) with nuclear staining DAPI (blue), overlapped
(arrows) in the right hand corners.

This upregulation of costimulatory molecules could promote T cell activation in
melanoma cells [144]. To examine further, J3.DR4.vec and J3.DR4.GILT cells were
stained with fluorescence-labeled anti-CD80/CD86 antibodies and analyzed by flow
cytometry. A slight increase in cell surface expression of CD80 and CD86 molecules was
observed, Figure 2.6.

39

0812 09dn.001

0812 09dn.003

M1
100 101 102 103 104
FITC
0812 09dn.005

M1

0812 09dn.009

M1
100 101 102 103 104
FITC
0812 09dn.013

M1
100 101 102 103 104
FITC
0812 09dn.017

Isotype

0812 09dn.008

101

102

J3.DR4.vec

M1

M1

100 101 102 103 104
FITC

103 104

FITC
0812 09dn.011

0812 09dn.012

M1

M1

100 101 102 103 104
FITC
0812 09dn.015

J3.DR4.GILT

100 101 102 103 104
FITC
0812 09dn.016

M1

M1

DM-331.vec

100 101 102 103 104
FITC
0812 09dn.020

100 101 102 103 104
FITC
0812 09dn.019

M1

M1

M1
100 101 102 103 104
FITC

100 101 102 103 104
FITC

0812 09dn.007

100

Frev

M1

100 101 102 103 104
FITC

M1
100 101 102 103 104
FITC

0812 09dn.004

DM-331.GILT

100 101 102 103 104
FITC

100 101 102 103 104
FITC

CD80

CD86

Figure 2.6 GILT expression minimally alters cell surface
expression of costimulatory molecules CD80 and CD86, but
significantly elevates intracellular CD80/CD86 in melanoma
cells. Flow cytometyric analysis of cell surface CD80 and CD86
molecules. J3.DR4.vec, J3.DR4.GILT, DM-331.vec, and DM331.GILT cells were stained with CD80-FITC and CD86-FITC, and
a rabbit IgG isotype control. Cells were then analyzed by flow
cytometry for cell surface expression of CD80 and CD86 molecules.
The B-cell line, Frev which constitutively express CD80 and CD86
molecules was used as a positive control. Data are representative of
at least three separate experiments.
However, further studies failed to detect a significant change in cell surface
CD80/CD86 molecules in additional melanoma lines (data not shown). This change in
CD80/CD86 expression could result from a variation of cell types. Interestingly, GILT
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expression significantly elevated intracellular CD80 and CD86 protein expression as
determined by western blot analysis (Figure 2.7), supporting my immunofluorescence
data (Figure 2.5). This indicates that GILT may play a role in the alteration of
CD80/CD86 molecules in melanoma cells.
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Figure 2.7 GILT-positive cells express higher levels of intracellular CD80 and CD86 protein expression. (A)
Western blot analysis of CD80 and CD86 molecules. Frev, J3.DR4.vec and J3.DR4.GILT, DM-331.vec, and DM331.GILT cells were subjected to western blotting for CD80 and CD86 molecules. β-actin was utilized as a
loading control. (B) Densitometric analysis was performed using β-actin as a reference protein band to quantitate
relative protein expression. Data are representative of at least three separate experiments. Significant differences
were calculated by student’s t test; *p<0.05, **p<0.01, ns=not significant.

GILT colocalizes with acidic cathepsins B and D in melanoma cells.
The importance of acidic cathepsins in class II Ag processing and presentation
cannot be overstated. Cysteinyl and aspartyl cathepsins are responsible for the
processing of self-Ags into smaller peptides for presentation to CD4+ T cells. Our
laboratory has previously shown that GILT expression upregulates active forms of
cathepsins [97, 139, 140], which may help processing of Ags/peptides for class II
presentation. GILT expression in melanoma cells may thus enhance the reductive
cleavage of self-Ags, allowing protein unfolding. These partially processed polypeptides
are very susceptible to degradation by acidic cathepsins. Without reductase/cathepsin
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activity, endogenous and exogenous Ags cannot be efficiently processed into functional
epitopes for class II loading, an adaptation used by melanoma cells to avoid immune
detection. Whether GILT is playing a direct role in governing this increase in cathepsin
protein expression or activity remains unknown. Therefore, J3.DR4.GILT cells were
cultured and analyzed through confocal microscopy to assess the localization of
cathepsins and GILT when co-expressed in melanoma cells. Cells were stained with
either rabbit anti-CatB or CatD, and co-stained with goat anti-GILT antibodies, followed
by rhodamine-conjugated anti-rabbit IgG and FITC-conjugated anti-goat IgG antibodies.
Live images were acquired using a Leica TCS SP2 AOBS confocal system and processed
with Leica software. In Figure 2.8, overlayed images from J3.DR4.GILT cells indicate
that GILT colocalizes with acidic cathepsins in endolysosomal compartments of
melanoma cells. This may imply a possible protein-protein interaction which could
govern the increase in cathepsin expression and activity.
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Figure 2.8 GILT colocalizes with cysteinyl and aspartyl cathepsins and enhances their
expressions in human melanoma cells. J3.DR4.GILT cells were stained with either
rabbit anti-CatB or CatD, and co-stained with goat anti-GILT, followed by rhodamineconjugated anti-rabbit IgG and FITC-conjugated anti-goat IgG antibodies. Live images
were acquired by using a Leica TCS SP2 AOBS confocal system and processed with Leica
software. Colocalization of GILT (green) with CatB (upper panel) and CatD (lower panel)
is indicated by yellow staining and arrows.

GILT expression enhances the activity of cysteinyl cathepsins B/S and aspartyl cathepsin
D in melanoma cells.
Due to the colocalization of GILT with acidic cathepsins, I further investigated
whether GILT influences cathepsin activity in human melanoma cells. While cysteinyl
Cat B processes Ags, Cat S degrades Ii into smaller intermediate peptides with the end
result being the class II-associated Ii peptide (CLIP) [92, 95, 145, 146]. Without this
critical reaction, the removal and degradation of Ii would not occur, which effectively
blocks peptide loading onto HLA class II molecules. Thus, I first examined the activity
of cysteinyl cathepsin B in J3.DR4.vec, J3.DR4.GILT, DM-331.vec, and DM-331.GILT
cells. Interestingly, Cat B activity was significantly increased (J3.DR4.vec=3,873 vs.
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J3.DR4.GILT=4,499.3, p≤0.05; DM-331.vec=1520.67 vs. DM-331.GILT=4272, p≤0.01)
in two different melanoma cell lines transfected with GILT (Figure 2.9). Similarly, Cat S
activity was significantly increased in GILT-transfected J3.DR4.GILT (12,348 vs. 7730,
p≤0.01) and DM-331.GILT (7,477 vs. 6521, p≤0.05) cells (Figure 2.9). However, there
were no significant changes in Cat L activity in DM-331.vec, and DM-331.GILT cells,
rather Cat L activity was relatively lower in J3.DR4.GILT cells when compared to
J3.DR4.vec cells (data not shown). It remains unclear why GILT had an alternative effect
on Cat L, although both Cat S and Cat L can process Ii, facilitating HLA class II
maturation [97]. Altogether, these results suggest that GILT expression enhances the
activity of cysteinyl cathepsins B and S in human melanoma cells. This increase in
protease activity in J3.DR4.GILT and DM-331.GILT cells may help generate a greater
pool of functional epitopes, contributing to enhanced Ag presentation.
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Figure 2.9 GILT expression enhances cysteinyl and aspartyl
cathepsin activity. Cell lysates obtained from J3.DR4.vec,
J3.DR4.GILT, DM-331.vec, and DM-331.GILT cells were
analyzed for cathepsins B, S and D activities as described in the
methods. Enhanced activities of cysteinyl/aspartyl cathepsins
were detected in melanoma cells expressing GILT, as compared
to cells lacking GILT. The experiments were repeated at least
three times and results expressed as mean fluorescence unit
SEM of triplicate wells, significance indicated as *p<0.05,
**p<0.01.

0

J3.DR4. J3.DR4.
vec
GILT

DM-331. DM-331.
vec
GILT

Cathepsin D is an integral acidic protease involved in Ag processing and exhibits
site-specific cleavage and splicing of Ags, which is important for short peptide loading
onto HLA class II molecules [95, 96]. An increase in cathepsin D expression and activity
would aid melanoma cells in enhanced Ag processing and presentation of class II-peptide
complexes to CD4+ T cells. Thus, I performed cathepsin D activity assays, and I
demonstrated that GILT expression upregulated cathepsin B enzymatic activity in two
unique melanoma cell lines (Figure 2.9), suggesting that GILT expression may be able to
generate more functional peptides for class II presentation and CD4+ T cell recognition.
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These findings also suggest that GILT expression enhances select cysteinyl and aspartyl
cathepsin enzymatic activity in melanoma cells, which would allow for an improved
processing and generation of melanoma Ags for HLA class II presentation.

Mass spectroscopy and fragmentation of cysteinylated versus reduced Igκ188-203 peptides.
Because GILT expression enhances cathepsins’ activity, I next sought to examine
whether GILT-positive melanoma cells generate a greater pool of functional peptides as
compared to GILT-negative cells. Melanoma cells J3.DR4.vec and J3.DR4.GILT were
incubated with whole Ag IgG for 6 hours in HBSS and supernatants were collected and
subjected to LC-MS mass analysis to search for functional (reduced) κ188-203 peptide.
A greater pool of reduced IgGκ188-203 peptide was present in J3.DR4.GILT cells as
compared to J3.DR4.vec cells, confirming GILT’s ability to functionally reduce antigenic
peptides needed for T cell recognition, shown in Figure 2.10. Mass spectroscopic
analysis also suggested that J3.DR4.GILT cells produced a greater pool of peptides as
compared to J3.DR4.vec cells (Figure 2.10).
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Figure 2.10 Mass spectroscopy and fragmentation of cysteinylated versus reduced Igκ188-203 peptides. (A)
Cysteinylation of the κ188-203 peptide was determined by the detection of ionized species at 954 m/z. (B) GILT catalyzed
the reduction of cysteinylated-κ188-203 as ionized species at 894 detected. (C) Extracted ion chromatograph of peptides
generated by J3.DR4 and J3.DR4.GILT cells. LC-MS mass spectrometry was performed on supernatant obtained from
J3.DR4 and J3.DR4.GILT cells fed with IgG. Data suggest that J3.DR4.GILT cells generated a greater pool of reduced
peptides.

Further analyses by LC-MS showed that a greater pool of oxidized peptides (77.9% vs.
40.7%) was generated by cells lacking GILT, when a cysteine-containing peptide was
analyzed (Figure 2.11). Interestingly, no major alterations were observed when a noncysteine-containing peptide was analyzed (Figure 2.12).
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Figure 2.11 Percent occupation of cysteine oxidation in supernatants obtained from cells with or without GILT. (A)
J3.DR4 and J3.DR4.GILT cells were fed with IgG in serum free HBSS for 4h. Supernatants were collected by
centrifugation and analyzed by mass spectroscopy as described in the methods. Extracted Ion Chromatograph (XIC) of the
peptide ALVLIAFAQYLQQCPFEDHVK identified in supernatants obtained from cells GILT. 831.66 is the mass of the +3
charge state for the peptide ALVLIAFAQYLQQCPFEDHVK with the cysteine chemically modified by iodoacetamide
(+57). 828.25 is the +3 charge state of ALVLIAFAQYLQQCPFEDHVK which contains a tri-oxidized cysteine. 1205.4 is
+3 charge state of the peptide ALVLIAFAQYLQQCPFEDHVKLVNEVTEFAK which contains a tri-oxidized cysteine and
1 trypsin missed cleavage. The percent occupation of oxidation was calculated using the area under the curve from the XIC
(the total area of the oxidized peptides divided by the total area of the peptide 100). Cells expressing GILT had a 40.7%
tri-oxidized cysteine while cells lacking GILT had a significantly higher level of oxidation with 77.9% of the peptide being
tri-oxidized. (B) Tandem MS spectra (MS/MS) of the reduced and oxidized forms of the peptides
ALVLIAFAQYLQQCPFEDHVK and ALVLIAFAQYLQQCPFEDHVKLVNEVTEFAK, with the cysteine detected as
either carbamidomethylated or tri-oxidized. The top spectra identified ALVLIAFAQYLQQCPFEDHVKLVNEVTEFAK
with the cysteine tri-oxidized with an Xcorr value of 5.39. The site of oxidiation was confirmed by the presence of the b14
ions 1610.8 (+1) and 805.9 (+2)) and the y18 ion 805.9(+2). The middle tandem MS spectrum was identified as
ALVLIAFAQYLQQCPFEDHVK with a trioxidized cysteine and an Xcorr value of 3.36. The site of oxidation was
confirmed by the presence of the b14 ions 1610.8(+1) and 805.9(+2) and the y8 ions 1022 (+1) and 511.7(+2). The bottom
MS/MS spectra was identified with an Xcorr of 4.78 as the peptide ALVLIAFAQYLQQCPFEDHVK, with the cysteine
carbamidomethylated. The modification was localized by the presence of the b14 ions 1619(+1) and 810(+2) and the y8 ion
516(+2).
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GILT transfected melanoma cells produce more functional epitopes for HLA class IImediated presentation to CD4+ T cells.
Since GILT expression enhanced both aspartyl and cysteinyl cathepsin activity in
melanoma cells, it was pertinent to investigate whether GILT expression in melanoma
cells could generate more functional peptides for HLA class II presentation and T cell
recognition. J3.DR4.vec and J3.DR4.GILT cells were incubated overnight with the
whole IgGκ in HBSS. Cell supernatants were collected, filtered by a 0.45µM filter, and
analyzed by mass spectrometry. Data obtained showed an increase in the generation of
the peptide pool in GILT expressing melanoma cells (~2x more peptide in J3.DR4.GILT
cells, based on Peak area analyzed), and that more oxidized peptides were found in the
supernatant of melanoma cells lacking GILT (Figure 2.12). These data suggest that GILT
expression may help produce more functional peptides for presentation via the class II
pathway.
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Figure 2.12 Percent occupation of methionine oxidation in supernatants obtained from cells with or without GILT.
Cells (J3.DR4 and J3.DR4.GILT) were fed with IgG in serum free HBSS for 4h. Supernatants obtained were analyzed by
mass spectroscopy. (A) Extracted ion Chromatograph (XIC) of the peptide AVMDDFAAFVEK identified in cell supernatants
obtained from J3.DR4 and J3.DR4.GILT cell. 672.5 was identified as the reduced form of peptide AVMDDFAAFVEK, and
determined to be the +2 charge state. The oxidized form of this peptide, 680.5 (+2 charge state) was below the quantitation
limit as a peak was unable to be extracted to calculate the area. Based on the areas of the unoxidized form of this peptide,
there is no significant change in oxidation of methionines in J3.DR4.GILT supernatant. (B) Tandem MS spectra (MS/MS) of
the reduced (672.1) and oxidized (680.1) forms of the peptide AVMDDFAAFVEK. The top spectra represent the oxidized
form of the peptide AVMDDFAAFVEK. This peptide was identified with an Xcorc value of 3.15. Localization of the
oxidized amino acid was determined by the presence of the b3 ion at 318.3 and the y10 ions at 1188.5 (+1) and 594.7 (+2).
The bottom spectrum was identified as the reduced peptide AVMDDFAAFVEK with an Xcorr of 3.53.

GILT expression enhances HLA class II-mediated Ag processing and presentation.
We have previously reported that GILT expression restores CD4+ T cell
recognition of human melanoma cells [101]. In an effort to further understand the role of
GILT in melanoma, melanoma cell lines J3.DR4.vec, J3.DR4.GILT, DM-331.vec, and
DM-331.GILT were incubated with the whole Igκ Ag overnight under the same medium
conditions. After incubation, cells were washed and co-cultured with the T cell
hybridoma line 2.18a, which recognizes Igκ188-203 epitope, for 24 hours. Cell
supernatants were stored, and the T cell production of IL-2 was quantitated by ELISA.
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Analysis of functional Ag presentation showed that GILT expression enhanced CD4+ T
cell recognition of melanoma cells, shown in Figure 2.13. This data supports the notion
that increased cathepsins’ enzymatic activity in GILT-expressing melanoma cells might
have induced enhanced Ag processing and presentation capability as well as T cell
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Figure 2.13 GILT expression enhances HLA class II-mediated antigen presentation and CD4+ T cell recognition of
tumors by producing a greater pool of functional epitopes. (A-B) Human melanoma cell lines J3.DR4.vec, J3.DR4.GILT,
DM-311.vec, and DM-311.GILT were incubated with whole Igκ Ag overnight at 37oC. Cells were then washed, and cocultured with the κ188-203 peptide specific CD4+ T cell hybridoma line (2.18a) for 24 h. T cell production of IL-2 in the culture
supernatant was measured by ELISA. The production of IL-2 is used as an indication of Ag presentation and T cell
recognition. Data are expressed as mean pg/ml +/- SD of triplicate wells of at least three independent experiments. *p<0.01.
(C-D) Melanoma cells J3.DR4.vec, J3.DR4.GILT, DM-331.vec, and DM-331.GILT were incubated overnight with whole Igκ
Ag in HBSS at 37oC. Cell supernatants were transferred to paraformaldehyde fixed J3.DR4.vec (C) and DM-331.vec (D)
cells for overnight at 37oC. Supernatants from GILT-expressing cells were also incubated with L-cystine (290 μM) as
described. Cells were then washed and co-cultured with the κ188-203 peptide specific CD4+ T cell hybridoma 2.18a for 24h. T
cell production of IL-2 was quantitated by ELISA. Data are representative of at least three separate experiments.*p<0.001.
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Tumor cells either lack GILT or express low levels of this protein, helping them
evade immune recognition. In this chapter, I have found that cells incubated with
cysteine-containing Ag were poor presenters of epitopes to T cells, and GILT expression
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helped or enhanced T cell recognition. To investigate if GILT-expressing cells are better
targets for T cells, cells +/- GILT were incubated with IgG in HBSS, and supernatants
collected were tested on J3.DR4.vec and DM-331.vec for their ability to stimulate CD4+
T cells as previously described in the Materials and Methods. Cells were fixed with 1%
paraformaldehyde to prevent internalization and processing of Ags, washed, and cocultured with the peptide-specific T cell hybridoma 2.18a. J3.DR4.vec cells incubated
with supernatant obtained from IgG-fed J3.DR4.vec cells did not optimally stimulate T
cells. By contrast, J3.DR4.vec cells incubated with supernatant obtained from IgG-fed
J3.DR4.GILT cells optimally stimulated T cells. Addition of oxidized cystine in the
J3.DR4.GILT-supernatant significantly downregulated epitope presentation by
J3.DR4.vec cells to T cells (Figure 2.13), indicating that GILT expression in tumors may
drastically become better targets for CD4+ T cells, and cysteinylation blocks T cell
recognition via the class II pathway. These data also suggest that epitopes generated by
GILT-expressing cells are presented by GILT-negative cells in the context of HLA class II
molecules.

Discussion & Conclusions
An important characteristic in the immune evasion of melanoma tumors is the
alteration of tumor Ag presentation or interruption in the HLA class II Ag presentation
pathway. Restoring the HLA Class II presentation pathway in melanoma cells has been
shown to support tumor destruction [97, 101]. However, melanoma cells lack an
important enzyme, GILT, perturbing epitope presentation via the HLA Class II
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machinery. Therefore, investigation of the role of GILT in the epitope generation for the
class II pathway and its involvement in stimulating CD4+ T cell recognition is essential
in the development of improved immunotherapeutic strategies.
In this study, we have shown that GILT enhances multiple components of the
HLA class II pathway, such as Ii and HLA-DM. Expression of Ii is important for
stabilizing HLA class II molecules by effectively forming a trimer within the
endoplasmic reticulum, thus regulating HLA class II presentation [147-149]. HLA-DM
acts as a peptide editor upon the class II DR complex to determine if the correct epitope
binds to the binding groove [150, 151]. Thus, DM can accelerate the reaction from
unstable to stable class II: peptide complex for immune recognition [97]. GILT
expression also enhanced intracellular expression of CD80/CD86, but this was not
translated on the cell surface. An increase in intracellular CD80/CD86 does correlate with
the expression on the cell surface [152]. However, this upregulation of costimulatory
molecules by GILT could lead to a reduction in T cell tolerance [153] and immune
avoidance by melanoma cells.
Professional APCs express high levels of GILT which is crucial for Ag processing
and presentation to CD4+ T cells. However, melanoma and other tumors, express low to
no detectable levels of GILT which could be correlated to the tumor cells’ inability to
display a broad repertoire of functional class II-peptide complexes on their cell surface to
T cells [111].
Professional APCs possess all the machinery to optimally processes and present
Ags to T cells while malignant tumor cells lack some of the processing machinery needed
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to generate a large repertoire of functional HLA peptide complexes necessary for a robust
CD4+ T cell response [97, 101, 102].By further understanding the steps and factors
involved in Ag processing reactions, new potential targets for immunotherapy may
emerge. This study suggests that GILT expression in melanoma cells enhances HLA
class II Ag processing. GILT expression also enhances the enzymatic activity of
cathepsins B, S, and D, which correlates with our previous finding that GILT causes an
increased expression of active forms of cysteinyl and aspartyl cathepsins [97].
Intracellular proteases such as cysteinyl cathepsins B and S are essential for degradation
of endogenous and exogenous Ags, and each serves an important role in the processing of
peptides for presentation via HLA class II molecules. Aspartyl cathepsin D activity was
significantly upregulated, which may contribute to the enhanced processing of selfAgs/peptides. This suggests that Ags, both endogenous and exogenous, may be readily
processed by GILT-expressing tumor cells, which could allow for more functional
epitopes available for presentation via the class II pathway [154]. The final event would
then end with an increase in immune recognition and a stronger anti-tumor immune
response. Since melanoma express their own tumor Ags such as NY-ES0-1, gp100, and
tyrosinase [155-157], the increase in enzymatic activity by GILT-expressing melanoma
cells could be exploited for the induction of tumor Ag-specific T cells. Further
understanding GILT’s role in Ag processing and presentation in melanoma may lead to
the development of new and more effective immunotherapeutics against metastatic
melanoma.
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The presence of GILT influences several key components of the class II pathway
in melanoma. It enhances the expression of the cathepsins and increases Ag processing
and presentation, leading to increased stimulation of CD4+ T cells. Other studies have
shown that GILT is important in the development of the overall T cell response to protein
Ags that contain disulfide bonds [97, 101, 103]. With the combination of GILTfacilitated reduction as well as proteolysis in the endosomal/lysosomal compartments in
melanoma cells, it is safe to assume that the generation of class II epitopes would be
enhanced, but this had never been tested. We present evidence that the pool of Ag
peptides/epitopes generated by the presence of GILT have increased functionality,
illustrating GILT’s ability to reduce oxidized or cysteinylated peptides to a more
functional form. This is also supported by the observed increase in GILT/cathepsins. The
presence of GILT produced more functional epitopes from whole Igκ, which then was
able to increase CD4+ T cell recognition and IL-2 production. This action was inhibited
when supernatant was incubated with the presence of cystine, which suggests that
cysteinylation inhibits peptide presentation and GILT expression may overcome
inefficient processing of self-Ags/peptides. Data presented here suggests that epitopes
generated by GILT-expressing cells are better recognized by CD4+ T cells than those of
GILT-negative cells. Enhancing the presentation of known melanoma Ags by GILTexpressing cells could be exploited through the whole cell vaccine immunotherapy
strategy. Allowing the generation of in vitro T cells with specific Ags expressed by
melanoma cells would also exploit immunological memory against reoccurring malignant
cells.
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Chapter 3: GILT expression negatively regulates PAX3 in human melanoma cells.
PAX3 and its Role in Melanoma Pathogenesis
Because of the aggressive nature and the immune avoidance by melanoma,
current research has focused on factors that amplify advanced disease. Recent studies
suggest that melanoma cells revert to an embryonic program of gene expression involved
in neural crest cell migration to support developmental plasticity and metastasis [158].
This includes studying molecules involved in melanocyte generation and differentiation.
One such factor that has been found in late stage melanomas is a transcription factor
called paired box 3 (PAX3). PAX3 is a transcriptional regulator involved in melanocyte
development as well as myogenesis and the development of the central nervous system
[159, 160]. PAX3 contains four domains: the paired domain, the homeodomain, the
octapeptide, and the transactivation domain. The paired domain facilitates protein-protein
interactions and DNA binding [72]. The homeodomain functions in regulating the DNA
binding ability of the paired domain [161, 162]. The octapeptide acts as a proteininteraction epitope while the transactivation domain mediates PAX3-DNA interactions
[161]. During embryonic development, neural crest cells express PAX3 while they
develop into melanoblasts and migrate to the epidermis. Here, melanoblasts differentiate
into melanocytes, and PAX3 is a key component in the migration and proliferation of
these cells [163]. PAX3 is also expressed in melanocyte stem cells, where it represses
terminal differentiation, retains the ability to enter the cell cycle, and inhibits apoptosis
[164-167]. Mutations in PAX3 result in Waardenburg syndrome which includes
abnormalities of the nervous system, eyes, nose, and pigmentation defects affecting skin,
hair, and otic pigment cells [168, 169]. Many mutations within PAX3 can result in
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Waardenburg syndrome, but most mutations occur in the paired domain [170]. PAX3
expression has also been found in medulloblastoma, benign peripheral glial tumor
neurofibroma, Erwin’s sarcoma, supratentorial primitive neuroectodermal tumor, gastric
cancer, and pediatric alveolar rhabdomyosarcoma [171].
When neural crest cells develop into melanoblasts and then melanocytes, PAX3 is
translocated to the nucleus via Importin13, and forms a complex with Sry-like HMG box
10 (SOX10) to activate Microphthalmia transcription factor (MITF) [172-174]. MITF is
crucial for melanoblast survival during and immediately following migration from the
dorsal neural tube to the migration staging area [160]. PAX3, SOX10, and MITF
determine the balance between melanocyte differentiation and maintenance of
melanoblast and melanocyte stem cells, which is Wnt-dependent [164, 175]. However,
once a threshold of PAX3 expression is achieved, PAX3 is downregulated, and later
phases of terminal differentiation continue [165]. MITF then signals to melanin synthesis
proteins Tyrosine related protein-1 (Trp-1), Tyrosinase (Tyr), and Dopachrome
Tautomerase (Dct) for complete melanocyte differentiation [164].
Along with melanoblast maintenance and melanocyte differentiation, PAX3 is
also involved in cell survival. Known anti-apoptotic factors like Bcl-Xl, p53, and PTEN
are direct downstream targets of PAX3. During embryogenesis, PAX3 is involved in
neural crest development through the inhibition of p53-mediated apoptosis [176]. PAX3
also inhibits PTEN expression, at least in myogenesis [177]. Increased expression of
PAX3 leads to PTEN downregulation and a decrease in apoptosis through the
PTEN/AKT pathway [178]. Transcription of Bcl-Xl is also directly regulated by PAX3 in
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rhabdomyosarcoma [179], and MITF regulates Bcl-2 in melanocytes and melanoma
[180]. The anti-apoptotic function of PAX3 aids in the migration of undifferentiated
cells, which may enhance melanoma cell survival.
Regulation of PAX3 is essential for melanocyte development. PAX3 protein
expression can be regulated by phosphorylation and ubiquitination. A Ser205
phosphorylation site within PAX3 has been found, but it has only been observed in
proliferating mouse primary myoblasts [181]. Ubiquitination of PAX3 has been shown in
adult muscle stem cells [182]. Also, PAX3 interacts directly with Death domain
associated protein (Daxx), which was found through its interaction with Fas/CD95 in the
cytoplasm [161]. Daxx acts as a repressor of transcription factors in the nucleus, where
Daxx may be mediated by STAT1 activation [183]. It binds to PAX3 through epitopes in
the homeodomain and the octapeptide regions [161]. The Daxx-mediated inhibition of
PAX3 can be blocked by the recruitment of Daxx to the nuclear bodies by promyelocytic
leukemia protein (PML). Daxx also inhibits a PAX3 direct downstream target receptor
tyrosine kinase MET [184]. This recruitment of Daxx to PAX3 can ultimately restrict the
development and differentiation of melanoblasts into melanocytes.
Multiple studies have looked into the relationship between STAT3 and PAX3.
STAT3 is a direct transactivator of the PAX3 promoter [185]. Mutant V600E BRAF
enhances STAT3 phosphorylation and increases PAX3 expression in melanocytes [186].
One study determined that silencing of STAT3 or PAX3 with siRNA was shown to inhibit
the growth of melanoma cells, particularly in melanoma cells that have acquired
resistance to vermurafenib [29].
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Another regulator of PAX3 is transforming growth factor beta (TGF-β), a
cytokine that controls numerous effects on multiple cells [187, 188]. These functions
include cellular behavior, differentiation, survival, migration, proliferation, and/or
adhesion [189]. TGF-β also protects homeostasis by acting as a tumor suppressor [190].
In melanoma cells, high levels of TGF-β are secreted within the tumor
microenvironment, but tumor cells fail to respond and growth inhibition is prevented
[191]. While there are other regulators of PAX3, TGF-β has an important role in the
maintenance of PAX3 in adult melanocytes. With limited UVR, keratinocytes residing in
the epidermal layer of the skin secrete moderate levels of TGF-β, which signals through
serine/threonine kinase receptor complexes (RI-RII) on the surface of melanocyte [192].
This binding at the cell membrane activates the Smad proteins to accumulate in the
nucleus, which then controls targets of the TGF-β/Smad complex [193, 194]. Once TGFβ is bound to the RI-RII receptor, R-Smad is phosphorylated and forms a complex with
Smad4 and Ski [195]. Ski forms this complex in melanocytes and directly inhibits the
transcription of PAX3 [196]. Another study also showed that treating melanocytes with
varying concentrations of TGF-β led to the down-regulation of PAX3 mRNA and protein
expression [196].
On the other hand, levels of TGF-β are reduced when keratinocytes are stimulated
with UVR. Studies suggest that TGF-β expression is also suppressed at both the
transcriptional and protein level following UVR of the skin [196-198]. The repression of
TGF-β is caused by the UVR-induced expression of both Jun N-terminal kinase (JNK)
and the tumor suppressor p53. Collectively, JNK and p53 activate the transcription of
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activating protein 1 (AP-1) [199, 200]. This allows p53 to stimulate the production of
pro-opiomelanocortin/melanocyte stimulating hormone (POMC/MSH) in keratinocytes
[23, 201], which releases the αMSH ligand that binds to the melanocortin-1 receptor
(MC1R) on the melanocyte cell surface [201]. Once the αMSH ligand binds to MC1R, a
signal cascade that works with adenylate cyclase (AC) leads to the production of cyclic
adenosine monophosphate (cAMP) [16]. As levels of cAMP reach a certain threshold, the
phosphorylation of cAMP response element binding transcription factor (CREB) occurs
via protein kinase A [201].
CREB stimulates both PAX3 and SOX10 which together form a complex to
activate MITF. MITF, the master regulator of melanocyte differentiation, plays multiple
roles in melanoma. Loss of MITF results in cell cycle arrest and apoptosis, moderate
levels lead to proliferation and survival, and increased expression results in
differentiation [180, 202]. MITF and PAX3 can also independently initiate the
expression of MET, which plays a role in cell migration and growth as well as in cancer
progression and metastasis [17, 203, 204]. However, when deregulation occurs, PAX3
may play a role in the pathogenesis of melanoma [160, 161, 164, 196, 205]. PAX3
expression is deregulated in a significant proportion of melanomas [206, 207] (Figure
3.1). PAX3 has been found in healthy melanocytes, benign nevi, and melanoma tumors
[206, 208-210]. PAX3 has also been used as a staging marker for melanoma and in the
detection of circulating melanoma cells [160, 211, 212]. PAX3 has been recognized as an
immunogenic protein, where it has been found in primary tumors as well as advanced
diseases such as stages 1 and 4 [213, 214]. This indicates that the regulation of PAX3
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could be an important facet in melanoma initiation, progression, and metastasis. The
direct role that PAX3 plays during intermediate stages of melanoma (i.e. II and III) must
be identified to better understand the process of melanoma progression. Given PAX3’s
expression in late stage metastatic melanoma but absence in intermediate stages, targeting
PAX3 could potentially shift the nature of melanoma tumors to a less aggressive, less
metastatic form.

Figure 3.1 PAX3 is differentially expressed in human melanoma tumors. Five melanoma tumor
samples of different stages were tested for PAX3 protein expression via western blot analysis.
Sample T3838 showed a marked PAX3 protein expression, which correlates with the highly
metastatic and late stage of the tumor. Four other melanoma patient samples did not express
detectable levels of PAX3 proteins. Further information from Hollings Cancer Center indicated that
T3838 was a stage 4 metastatic tumor with invasive bone metastasis. The other four samples either
were not early stage tumors, or the metastasis information was not provided.

Previous studies have shown that GILT enhances HLA class II presentation and T
cell recognition. If GILT has this secondary role in improving cancer cell aggressiveness,
PAX3 would be a good candidate see if GILT has any effect on its gene/protein
expression. PAX3 is known as a transcription factor in the differentiation of
melanocytes, and is implicated in tumorigenesis and anti-apoptosis. If GILT can alter
expression of PAX3, it may be able to reduce the cells to a less aggressive, less metastatic
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form. Thus if GILT insertion can alter the expression of PAX3, it may be able to reduce
the cells to a less aggressive, less metastatic form, while shedding light on the potential
benefit of targeting PAX3 in the design future melanoma immunotherapy.

Hypothesis
I tested the hypothesis that GILT expression downregulates PAX3 molecules in
human melanoma cells via protein-protein interaction, activation of autophagy and
lysosomal degradation pathway.

Research Strategy
Experiment 1: Examined PAX3 and Daxx gene expression in melanoma cells +/GILT.
Experiment 2: Determined GILT, PAX3, and Daxx protein expressions in
melanoma cells +/- GILT.
Experiment 3: Studied the relationship between PAX3 and Daxx in human
melanoma cells.
Experiment 4: Analyzed multiple GILT mutants to determine its effect on PAX3
expression.
Experiment 5: Investigated the pathway GILT utilizes to regulate PAX3 and
downstream targets in GILT +/- melanoma cell lines.

Materials and Methods
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Cell lines
Human melanoma cell lines DM-331, HT-144, and J3.DR4.vec were cultured as
described in Chapter 2 and were used in these experiments. The human melanoma cell
line J3 was cultured in the same media conditions, but was transfected with a mutated
GILT protein where cysteine at position 46 was mutated to a serine (Dr. Suzanne
Ostrand-Rosenberg, University of Maryland, Baltimore, MD).
Table 3.1 Cell lines utilized for chapter 3.
Melanoma Cell Line

Conditions/Treatments

Reason for use

J3.DR4

+/- GILT, +/- C46S
GILT mutant, +/- 20nM
bafilomycin

HT-144

+/- GILT

Retrovirally transduced to express
DR4, to determine role of GILT in
PAX3 regulation, displayed high
levels of PAX3
Constitutive expression of DR4, to
determine the role of GILT in
PAX3 regulation, displayed high
levels of PAX3

DNA transfection assays
Human melanoma cell lines DM-331, HT-144, and J3.DR4 were transfected with
a plasmid encoded with GILT cDNA and a puromycin drug resistance gene or a vectorencoded plasmid with the same puromycin drug resistance gene using a lipofectamine
transfection reagent (Sigma-Aldrich, St. Louis, MO) as described in Chapter 2 of this
study.

Preparation of cell lysates & Protein determination
Transfected cells were grown to 80% confluence and subjected to complete lysis
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buffer, and cell lysates were assessed for protein concentration as previously described in
this study.

Western blotting
Once protein levels were quantified following cell lysate and protein
determination, equal concentrations of vector and GILT matched cell lines were run onto
a NuPAGE 4-12% gel and transferred as previously described in this study.

Antibodies and reagents
Nitrocellulose membranes were subjected to probing with various antibodies.
The antibodies used were PAX3 (Santa Cruz), Daxx (Santa Cruz), Beclin-1(Santa Cruz),
LC3 (Bioscience), GILT (Santa Cruz), and Actin (Santa Cruz). Nitrocellulose
membranes were incubated for 2-3 hours, rolling, at room temperature with a given
antibody at a predetermined concentration (as per manufacturer standard) in a solution of
2.5% milk in TBS-T. Following incubation time, blots were washed for 30 minutes in
TBS-T before being probed with antibody species specific secondary antibodies (antigoat, anti-rabbit, and anti-mouse IgG, Invitrogen and Santa Cruz) for one hour. Finally,
blots were washed again in TBS-T for 30 minutes then subjected to Luminata Crescendo
Western HRP Substrate (Millipore Corporation, Billerica, MA) and assessed as described
in western blot methods. Images were taken using BioRad GelDoc XRS photocenter
while subjected to ultraviolet light. Bafilomycin A1 (InvivoGen) was diluted to 20nM in
culture medium and used to block autophagy in melanoma cells overnight.
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Confocal microscopy
HT-144.vec and HT-144.GILT cells were grown to 80% confluence to then be
subjected to staining via confocal microscopy as described in Chapter 2 of this study.

Immunoprecipitation
Transfected cells were grown to 80% confluence and collected as a pellet in a
15ml conical tube and stored at -80oC until use. Cell lysis was performed as previously
described with about 200 µg-500 µg of protein needed. 60 µl of protein/bead mix per
sample tube was aliquotted and spun down for 10 seconds at 10,000 rpm. Supernatant
was removed and beads were placed on ice. Protein determination provided the
appropriate amount of cell lysate needed along with adding complete lysis buffer to tubes
containing the beads to reach a total volume of 300 µl. Tubes were then placed on the
rotator at 4oC for 2 hours. Samples were spun down for 2.5 minutes at 10,000 rpm and
supernatant was transferred to a new tube while pellet was discarded. GILT antibody
(Santa Cruz) was used to pull down proteins in these cells and it was added at a 1:100
dilution to the supernatant. Tubes were then placed on the rotator at 4oC for 1 hour. Bead
mix previously described was performed and added to the cell lysate/antibody mixture in
each tube containing protein beads. Tubes were placed on the rotator at 4oC overnight.
Next, samples were spun down for 5 minutes at 10,000 rpm and supernatant was
aspirated. 800 µl of wash buffer (cell lysis buffer without protease inhibitors) was added
to each tube and spun for 5 minutes at maximum speed. Supernatant was aspirated and
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the wash step was repeated for a total of 4 washes. During the last wash, a master mix of
lysis buffer (8 µl/sample), 4x sample buffer (8 µl/sample), and DTT (4 µl/sample) was
prepared for all samples. After aspirating the final wash step, 20 µl of the master mix
was added to each sample. Samples were then heated on at heat block at 100oC for 10
minutes. Samples were quickly spun down for about 10 seconds and 15 µl of each
samples was loaded onto NuPAGE 4-12% Bis-Tris gels (Invitrogen) and run at 200 volts
for 50 minutes. Bis-Tris gels containing protein were then transferred to nitrocellulose
membranes (Osmonics) employing a transfer chamber subjected to 30 volts for one hour.
Nitrocellulose membranes were then removed and blocked in a solution of 5% milk in
TBS-T overnight at 4oC. After incubation, the nitrocellulose membranes were probed
with protein specific mAbs. Probed nitrocellulose membranes were next assessed using
autoradiography film, following incubation with 3ml of Luminata Crescendo Western
HRP Substrate (Millipore Corporation, Billerica, MA) for 3 minutes. Autoradiography
films were scanned using a Canon MP250 scanner/printer and analyzed using a BioRad
Geldoc XRS photocenter, where densitometric software enabled for the quantification of
protein densities.

Statistical Analysis
Data from each experimental group were subjected to statistical analysis.
ANOVA with post-hoc tests, Repeated Measures ANOVA with post-hoc tests, or
Student’s t-tests were used, as appropriate. Student’s TTEST was performed on a
minimum of three independent values to determine significance. Significance was then
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determined as having a p value less than or equal to 0.05 as represented by an asterisk, or
less than or equal to 0.01 as represented by a double asterisk. The standard deviation of
all recorded values for a given experiment were also determined and are represented by
error bars on all figures, this data is representative of all obtained values for each given
figure with an N of at least 3. Finally, densitometry was performed on all electrophoresis
gels, using a BioRad GelDoc XRS photocenter. Using contoured image selection
software a relative density for each primer band was determined, along with a density
value for its corresponding actin band. Density readings were taken in triplicate using
three contoured readings: one tight, one medium, and one wide contour image for each
band was used. Each primer band density was then divided by the recorded density of its
corresponding actin yielding a relative density for each band. These data were then used
to generate both significance and standard deviations as determined above. Two-sided
tests were used in all cases and P values <0.05 were considered statistically significant.

Results
GILT downregulates PAX3 and upregulates Daxx proteins in human melanoma cells.
PAX3 has been indicated in melanoma tumorigenesis and metastasis [17, 203].
Therefore, targeting PAX3 may lead to a less aggressive state of melanoma. First, PAX3
expression had to be established in melanoma cell lines. In Figure 3.2, HT-144 cells
were stained with PAX as well as SOX10 and MITF, and confocal microscopy confirmed
PAX3 expression in the cytosol of these cells.
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Figure 3.2 PAX3, SOX10, and MITF expression in human melanoma cells. HT-144 cells
expressed the highest levels of PAX-3 and were tested for nuclear staining using confocal
microscopy. However, PAX-3 is mainly expressed in the cytosol. Cells were also tested for the
downstream molecules SOX10 and MITF using confocal microscopy. Staining confirms that both
molecules are expressed in these cells.

To determine if GILT would have an effect on such tumorigenic molecules, I tested GILT
transfected melanoma cell lines for PAX3 expression. Whole cell lysates were prepared and
tested through western blot analysis for PAX3 showed expression in cell lines J3.DR4.vec,
HT-144.vec, and DM-331.vec (Figure 3.3). Whole cell lysates were determined due to the
main location of PAX3 is in the cytosol. As shown in Figure 3.6, the insertion of GILT
effectively and significantly downregulated PAX3 protein expression in all three cell lines.
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(A)

(B)

(C)
PAX3

Daxx

Figure 3.3 GILT expression alters PAX3 and Daxx proteins in human melanoma cells. Melanoma cell lines J3,
HT-144, and DM-331 were stably transfected with vector or GILT cDNA as described in the methods. (A) Western
blot analysis for PAX3 and Daxx protein expression in melanoma cell lines +/- GILT. β-actin was used as a loading
control. Densitometric analysis of the protein bands detected in Figure 1b. β-actin was used as a reference to
quantitate the relative expression of PAX3 (B) and Daxx (C) proteins in both vector- and GILT-transfected J3, HT144 and DM-331 melanoma cells. Data suggest that GILT expression significantly reduces PAX3 proteins while
upregulating Daxx proteins in human melanoma cells. * = p <0.05

Daxx may be regulated through a STAT1-dependent pathway [183]. Our lab has
already shown that GILT is regulated by STAT1, not CIITA [109]. Because of the
downregulation of PAX3 observed in GILT-positive cells compared to GILT-negative cells,
GILT may be utilizing Daxx as an intermediate in the negative regulation of PAX3 via
STAT1. Therefore, I tested the same melanoma cell lines +/-GILT, and western blot analysis
determined a significant increase of Daxx protein expression in all GILT transfected cell
lines (Figure 3.3).
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GILT colocalizes with PAX3, not Daxx, in human melanoma cells.
Due to GILT's effect on PAX3 expression, I next examined the mechanism GILT
utilized to downregulate PAX3 expression. As previously stated, GILT is localized within
endosomal/lysosomal compartments while PAX3 is found both in the cytosol and within the
nucleus. Confocal microscopy was used to determine if GILT and PAX3 had any direct
interactions within the cell. Using the melanoma cell line HT-144.GILT, confocal
microscopy revealed that GILT and PAX3 do in fact colocalize together within the cell, as
seen in Figure 3.4. Based on the protein expression results, I tested whether Daxx and GILT
also colocalize within the cell. Both Daxx and GILT are regulated through STAT1 signaling.
Due to this similarity, Daxx may be acting as the intermediate protein resulting in PAX3
reduction. I used confocal microscopy on HT-144.GILT cells to determine if a proteinprotein interaction between GILT and Daxx existed in these cells. However, there was no
observable colocalization between GILT and Daxx (Figure 3.4). This finding is incredibly
interesting, as PAX3 has never been found localized within endosomal/lysosomal
compartment, as the finding with GILT suggests. These data supports the notion that GILT is
interacting with PAX3 through a possible protein-protein interaction, resulting in its
downregulation.
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(A)

(B)
Figure 3.4 GILT colocalizes with PAX3 molecules in HT-144.GILT melanoma cells. (A)
HT-144.GILT melanoma cells were subjected to confocal microscopy using antibodies against
GILT (left panel, green arrows) and PAX3 (middle panel, red arrows) proteins. Overlay shows
colocalization of PAX3 and GILT proteins (right panel, yellow arrows) in HT-144.GILT cells.
Bar, 26.1 µM. (B) Confocal microscopy of HT-144.GILT cells for Daxx (left panel, green) and
GILT (middle panel, red) molecules. Overlay shows no colocalization of Daxx and GILT
proteins (right panel, red arrows) in HT-144.GILT cells. Bar, 17.6 µM. Data are representative
of three separate experiments.

GILT interacts with PAX3 proteins in human melanoma cells.
Immunoprecipitation was used to definitively prove the direct interaction between
these two proteins (Figure 3.5). Following the immunoprecipitation protocol outlined in the
methods section of this chapter, IP GILT was used to pull down all of the proteins, which
directly bind and interact with GILT within the cell. IB probing of this extracted lysate for
PAX3 confirmed a direct protein-protein interaction between GILT and PAX3 in both
J3.DR4.vec and HT-144 melanoma cell lines. These results are confirmed as GILT specific
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through the control lysate which used a nonspecific NN4 antibody IP, followed by PAX3
probing IB.

Figure 3.5 GILT interacts with PAX3 proteins through a direct protein-protein interaction
in human melanoma cells. Co-immunoprecipitation studies in J3.GILT and HT-144.GILT cells
for GILT/PAX3 proteins using antibodies against GILT proteins. The NN4 antibody was used
as an isotype control. Immunoblotting was performed by using antibodies against PAX3 and
Daxx molecules. Data are representative of at least three separate experiments.

Functional GILT is required for PAX3 downregulation in human melanoma cells.
To further investigate the role of GILT in the negative regulation of PAX3, I
tested whether functional GILT was necessary for the decrease in PAX3 protein. A
previous study was done to test multiple GILT mutants [215]. It was observed that when
the cysteine at position 46 was mutated to a serine within the GILT protein, cells
expressed the mature GILT form at 30kDa, but did have reductase activity. Therefore,
this mutant GILT was transfected into the J3 cell line by the Ostrand-Rosenberg lab, and
this cell line was tested for PAX3 protein expression. Western blot analysis in Figure 3.6
determined that J3.DR4.vec cells expressed high levels of PAX3. With the insertion of
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GILT, there is a markedly decrease in PAX3 expression. However, in J3 cells transfected
with mutated GILT, PAX3 proteins recover to levels similar to J3.DR4.vec cells. These
data suggests that functional GILT is required for the downregulation of PAX3 protein in
human melanoma cells.
(A)

(B)

Figure 3.6 GILT induction regulates PAX3 protein expression in melanoma cells. (A) J3.Vec,
J3.GILT and the cysteine mutant J3.GILT.C46S were analyzed by western blotting for steady state PAX3
protein expression. β-actin was used as a loading control. (B) Densitometric analysis of the protein
bands detected in Figure 1b. β-actin was used as a reference to quantitate the relative expression of
PAX3 proteins in J3.vec, J3.GILT, and the mutant J3.GILT.C46S melanoma cells. Data suggest that
functional GILT expression is required in the downregulation of PAX3 in human melanoma cells. * = p
<0.05

GILT expression regulates PAX3 through the autophagy and lysosomal degradation
pathway in human melanoma cells.
GILT resides with the endosomal/lysosomal compartments of cells, while PAX3
mainly is expressed in the cytoplasm [161]. It was previously shown that GILT
expression downregulates PAX3 through a protein-protein interaction, and functional
GILT is necessary for this decrease. However, the mechanism underlying the interaction
between GILT and PAX3 remains to be elucidated.
Autophagy is a lysosome-dependent degradation process designed to maintain
cellular homeostasis by clearing damaged cytosolic organelles and long-lived proteins
[216]. It can be activated under cellular stress such as nutrient starvation, pathogen
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infection, and under pathological conditions, including vascular diseases,
neurodegenerative diseases, and cancer [217]. Once autophagy is activated, this process
helps reduce oxidative damage and maintains redox homeostasis [218].
Therefore, autophagic proteins were tested in melanoma cell lines +/- GILT
insertion through western blot analysis (Figure 3.7). The cell lines J3.DR4 and HT-144
were chosen for this experiment, due to the high levels of PAX3 in the vector cell lines,
and the significant downregulation when transfected with GILT. Results indicate that
GILT expression increased Beclin-1 proteins while decreasing LC3 protein. The
presence of GILT affects multiple proteins involved in autophagy. Because GILT is able
to downregulate PAX3, it is possible that GILT is leading PAX3 through the lysosomal
degradation pathway.
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Figure 3.7 GILT expression affects multiple proteins involved in autophagic processes. (A) Western blot analysis
of whole cell lysates from J3.DR4.vec, J3.DR4.GILT, HT-144.vec, and HT-144.GILT cells showing protein expression
of Beclin-1 and LC3. β-actin was utilized as a loading control. (B-C) Densitometric analysis for each protein tested,
which was significant in Beclin-1 and LC3 for HT-144.GILT cells, as indicated by *. Data are representative of at least
three separate experiments.*p<0.05, **p<0.01.

To test whether GILT regulates PAX3 through this pathway, cells were treated
with 20nM bafilomycin overnight. Bafilomycin has been shown to inhibit the late phase
of autophagy. This treatment prevents maturation of autophagic vacuoles by inhibiting
fusion between autophagosomes and lysosomes. Therefore, J3.DR4 +/- GILT expression
were treated with bafilomycin overnight, whole cell lysates were obtained, and subjected
to western blot analysis. Shown in Figure 3.8, J3.DR4 cells were probed for PAX3 as
well as Beclin-1 and GILT. When cells are treated with bafilomycin, there is a
significant increase in PAX3 expression, specifically in GILT positive cells. Beclin-1
and GILT were used as controls to determine the effectiveness of bafilomycin treatment.
This data suggests that when autophagy/lysosome is blocked, PAX3 expression is able to
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endure. When GILT is present in melanoma cells. GILT is able to regulate PAX3
through the autophagy and lysosomal degradation pathway.
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Figure 3.8 GILT regulates PAX3 through the autophagy and lysosomal degradation pathway. (A) Melanoma cell
lines J3.DR4 and J3.DR4.GILT were treated with or without 20nM bafilomycin overnight, which blocks proteins from
processing via the lysosomal degradation pathway. Western blot analysis from whole cell lysates of these cell lines
were probed for PAX3, Beclin-1, and GILT expressions. β-actin was utilized as a loading control. (B-C) Densitometric
analysis for each protein tested, which was significant in J3.DR4.GILT cells with or without bafilomycin, as indicated
by *. Data are representative of at least three separate experiments.*p<0.05, **p<0.01.

Discussion & Conclusions
The major focus of this chapter was related to PAX3 and its signaling and their
influence in late stage melanoma. PAX3 is a tumorigenic and immunogenic molecule that is
susceptible to targeted therapies [87]. Only in this study, results presented earlier in this
chapter showed that the insertion of GILT in melanoma cells led to a downregulation in both
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PAX3 mRNA and protein expression. PAX3 has also been indicated in late stage metastatic
melanoma. This has been confirmed in melanoma patient tumors and finding PAX3
expression in a stage IV melanoma tumor, where metastasis was present in the brain as well
as bone. These results indicate that PAX3 may be an important factor in facilitating late stage
metastasis.
To examine PAX3 regulation, I investigated the protein Daxx, because it has been
shown that it binds to PAX3 and inhibits its expression [68]. Studies have shown that both
GILT and Daxx are regulated through STAT1 signaling [60, 101]. Data in this study showed
that GILT insertion enhanced Daxx expression at the proteins levels. However, confocal
microscopy showed that GILT does not colocalize with Daxx in melanoma cells. This result
indicates that although GILT and Daxx may not have a direct relationship with one another,
Daxx may still have an effect on the decrease of PAX3 protein expression.
Once ruling out the indication that GILT was using Daxx in the regulation of GILT,
GILT’s direct role on PAX3 expression was examined. For the first time, results show that
GILT and PAX3 colocalize together in melanoma cells through the use of confocal
microscopy. Immunoprecipitation confirmed this result, determining that GILT directly
interacts with PAX3 in a protein-protein interaction leading to its reduction. This finding was
further enhanced when a GILT mutant was transfected into the J3.DR4.vec cell line and
tested for PAX3. With the mutant GILT having the protein expression but no reductase
activity, it was found that PAX3 expression was recovered to almost control levels. Data
suggests that functional GILT is required for PAX3 downregulation.
Never before has it been documented that GILT would have any effect on PAX3,
because GILT is localized in the endosomal/lysosomal compartments while PAX3 is mainly
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in the cytosol and partially in the nucleus [52, 67]. Within the endosomal/lysosomal
compartments, proteins may trafficked through and tagged for autophagy through the
lysosomal degradation pathway. Knockdown of PAX3 expression in melanoma cells can
lead to reduced or arrested cell growth, and induction of apoptosis and/or senescence [158,
206, 219] These results support the notion that PAX3 is susceptible to targeting, which could
lead to a less metastatic phenotype of this disease.
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Chapter 4: Modulation of GILT and PAX3 by Ganoderic acid DM enhances
radiation and chemoimmunotherapy of melanoma.
Introduction
In metastatic melanoma, standard treatments alone such as radiation,
chemotherapy, and immunotherapies have been ineffective when treating this disease.
Despite toxicities, high-dose radiation and chemotherapeutic drugs have become a
general mainstay for cancer treatment, destroying cancer cells by inducing apoptosis
[220]. However, it has become increasingly important to search for natural products that
are less toxic and can produce favorable immune responses. One such candidate for
antitumor responses is the Ganoderma lucidum mushroom. For thousands of years, the
G. lucidum mushroom has been used in herbal medicine where it was initially thought to
maintain vitality and increase life expectancy [221]. It was reported that G. lucidum
presented a wide array of biological effects including prevention of chronic diseases, such
as hepatitis, hepatopathy, hypertension, and cancer [222, 223]. Recent research suggests
that the Ganoderic acid extracts from this mushroom may have wide-ranging medicinal
benefits, most notably its toxicity to tumor cells with limited toxicity to healthy bystander
cells [223]. Various Ganoderic acid subtypes have been tested for efficacy in multiple
inflammatory and malignant diseases such as inflammation, bronchitis, and cancer [224226]. Crude extracts of the G.lucidum mushroom have shown cytotoxicity in various
tumor cell lines [227-231]. Among the active compounds in G. lucidum, triterpenoids
have been demonstrated as one of the main components responsible for pharmacological
activities including immunomodulation, anti-oxidative, anti-metastasis, and anti-tumor
effects [232-234]. Of all the extracts, Ganoderic acid DM (GA-DM) has the most
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hydrophobic structure and is devoid of interfering hydroxyl or acetyl side chain groups.
GA-DM has been found to inhibit osteoclastogenesis by regulation of c-Fos and nuclear
factor of activated T cells c1 and exerts anti-prostate cancer effects partially via inhibiting
5α-reductase activity [226, 235]. While the effects of Ganoderic acids on breast, lung,
and prostate cancer cell lines have been well-established [223, 226, 229, 231, 236-238],
much less was known about its potential role as a therapeutic agent in metastatic
melanoma.
Our lab is the only group to test GA-DM on melanoma cell lines. We have shown
that GA-DM could influence intracellular machinery of melanoma cells for HLA Class II
processing and presentation to T cells for immune recognition [239]. We also showed
that GA-DM treatment induces autophagic and apoptotic events as well as immune
activation in human melanoma cells. GA-DM treatment showed an increase in caspase 9,
caspase 3, bcl-2-like protein 4 (Bax), cytochrome c, and apoptotic protease activating
factor 1 (Apaf-1), a possibly activated extrinsic pathway of programmed cell death
(Figure 4.1). Anti-tumor efficacy of GA-DM in B16 melanoma model in vivo was
investigated and demonstrated a slowed tumor progression with a significant reduction in
tumor volume [239]. These findings suggest a huge potential of GA-DM as an
immunotherapeutic agent for treating malignant melanoma.
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Figure 4.1 GA-DM affects apoptotic and autophagic proteins in human
melanoma cells. (A) J3.DR4.vec cells were treated with GA-DM overnight and
stained for cytochrome c and Apaf-1 proteins through confocal microscopy. In
overlayed images of cells treated with GA-DM, an increase in cytochrome c
release and Apaf-1 proteins is observed compared to vehicle. (B) Western blot
analysis of J3.DR4.vec cells treated with GA-DM indicates activation of caspase 3
with cleaved caspase 3p17 expressed. (C) Autophagic protein Beclin-1 shows
higher protein expression in J3.DR4.vec cells treated with GA-DM compared to
vehicle, suggesting that melanoma cells are undergoing autophagic processes. βactin was used as a loading control in (B) and (C). Data is representative of 3
independent experiments.

As previously stated, our lab has tested the efficacy of GA-DM on multiple
human melanoma cell lines. Figure 4.2 is a proposed model of what is happening when
melanoma cells are treated with GA-DM. As shown, it is postulated that DNA damage is
occurring, leading to an increase in p53 while reducing Mouse double minute 2 homolog
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(MDM2). The activation of p53 leads to p21 increased expression, and p21 is able to
block the binding of CDK4 with Cyclin D. CDK4 and Cyclin D are cell cycle regulators,
and when this is disrupted, G1 cell cycle arrest occurs. This will ultimately lead to tumor
suppression. There are many other targets that may be involved in GA-DM-mediated
melanoma cell death. Such molecules like the BH3-only proteins as well as apoptotic
proteins may play a role leading to cellular death. It is currently unknown whether this
treatment has any effect on these molecules.
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Figure 4.2 A hypothetical model for testing the effects of GA-DM on melanoma
growth in vitro and in vivo. This diagram is a hypothetical signaling pathway when
melanoma cells are treated with GA-DM. When cells are treated, it is postulated that DNA
damage is occurring, leading to an increase in p53 while downregulating Mdm2. This will
lead to an increase in p21, thus blocking the binding of Cyclin D with CDK4, leading to
G1 arrest of melanoma cells and ultimately tumor suppression.
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Understanding the role of GILT on PAX3 reduction may allow melanoma cells to
be sensitized to radiation treatment, a commonplace treatment of melanoma patients. In
addition, GA-DM has been shown to induce apoptotic protein expression. Utilizing a
combination treatment of radiation and GA-DM may induce cellular death while
enhancing immune responses. My preliminary data suggests GILT insertion sensitizes
melanoma cells to radiation therapy. Other studies have also found that knockdown of
PAX3 expression in melanoma cells can lead to reduced or arrested cell growth, and
induction of apoptosis and/or senescence [158, 206, 219]. Because of the preliminary data

of GILT decreases PAX3 protein expression as well as the role of PAX3 in cell survival,
blocking PAX3 expression could allow melanoma cells to be susceptible to cellular death.
This indicates that GILT may be a possible target in immunotherapy. Because GILT may
downregulate PAX3 to sensitize cells to radiation therapy, this simultaneous targeting of
GILT and PAX3 by GA-DM may enhance radiation and chemoimmunotherapy of
melanoma in vivo.
On the other hand, ionizing radiation has been used for treatment for cancer for
more than 100 years [240]. Recent studies have shown that endogenous type I
interferons (IFNs) play a role in radiation-mediated anti-tumor immunity by enhancing
the ability of dendritic cells to cross-prime CD8+ T cells [241]. It was previously stated
that radiation therapy has had some success when combined with multiple
immunotherapies [53, 56, 57]. To further investigate the role of radiation therapy, in vivo
studies have been done to test the efficacy of this treatment. One study revealed that
antitumor immune responses were present in a B16 mouse model receiving either 15Gy
single dosage or fractionated (5 x 3Gy) of localized ionizing radiation [242]. It was
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found that local tumor irradiation increases the Ag-presenting capability within tumordraining lymph nodes and increases the numbers of T cells within tumor-draining lymph
nodes that secrete IFN-γ upon tumor peptide stimulation [242]. Radiation also increased
the numbers of immune cells infiltrating the tumors, including TILs that both secrete
IFN-γ upon tumor peptide stimulation and exhibit lytic activity [242]. Another in vivo
study displayed similar results that radiation-induced type I IFNs play a role in increasing
CXCR3 chemokine levels within the tumor, which affects the initial recruitment of
immune cells into the tumor microenvironment, when using the B16 mouse model and
local single high-dose radiation (15Gy) treatment [240]. This study also showed the
increasing intratumoral IFN-α levels exogenously after radiation, to further improve the
ability of the therapy to bring about tumor control. These studies, as well as others,
indicate a positive immune, anti-tumor response when malignant cells are treated with
radiation therapy in vivo.
Radiotherapy combined with multiple immunotherapies have shown promise, as
previously described in Chapter 1 of this study. With the low success rates of current
treatments for melanoma, the treatment strategy of combining GA-DM as an
immunotherapy and radiation as the standard treatment would be ideal in destroying
cancer cells while simultaneously increasing antitumor immunity.

Hypothesis
I tested the hypothesis that Ganoderic acid DM modulates GILT and PAX3 to
enhance radiation and chemoimmunotherapy of melanoma.
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Research strategy
Experiment 1: Examined cell viability of GILT +/- melanoma cells after varying
radiation, GA-DM, and the combined GA-DM/radiation treatments.
Experiment 2: Investigated apoptotic molecules (p53, caspase 3, caspase 9, etc.) and
cell cycle checkpoints (Cyclin D, CDK4, p21, etc.) in GILT +/- melanoma cells
subjected to radiation, GA-DM, and the combined GA-DM/radiation treatments.
Experiment 3: Analyzed tumor volume and survival in no treatment, radiation, GADM, and the combined GA-DM/radiation treatment utilizing the murine B16
melanoma model.
Experiment 4: Analyzed cytokine production, T cell infiltration, and other immune
components (MDSCs, M2, etc) in no treatment, radiation, GA-DM, and the combined
GA-DM/radiation treatment in vivo.

Materials & Methods
Cell lines
Human melanoma cell lines HT-144.vec and J3.DR4.vec were cultured as
described in Chapter 2. The B16 mouse melanoma cell line was a gift from Dr. Mark
Rubinstein (Medical University of South Carolina, Charleston), and was cultured in
complete RPMI supplemented with HEPES and non- essential amino acids Invitrogen) as
described previously. B16/Ab mouse melanoma cell line, which was transfected to
express MHC class II, was a gift from Dr. Suzanne Ostrand-Rosenberg (University of
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Maryland, Baltimore, MD). It was cultured in complete RPMI supplemented with FBS.
The mouse T cell hybridoma BO4, which is specific for HEL74-88/I-Ab was maintained in
complete RPMI supplemented with 10% FBS + β-ME.
Table 4.1 Cell lines utilized for chapter 4.
Melanoma Cell Line

Conditions/Treatments

Reason for use

J3.DR4

+/- GILT, +/- 20uM GADM, +/- 5-20Gy

HT-144

+/- GILT, +/- 20uM GADM, +/- 5-20Gy

B16

+/- 20uM GA-DM, +/5-20Gy, +/- Ab (MHC
class II)

Retrovirally transduced to express
DR4, to determine role of GILT in
PAX3 regulation in vitro,
displayed high levels of PAX3
Constitutive expression of DR4, to
determine the role of GILT in
PAX3 regulation in vitro,
displayed high levels of PAX3
Constitutive expression of PAX3
and GILT, mouse melanoma to
determine treatment efficacy in
vivo

DNA transfection assay
Human melanoma cell lines HT-144.vec and J3.DR4.vec were transfected with a
plasmid encoded with GILT cDNA and a puromycin drug resistance gene or a vectorencoded plasmid with the same puromycin drug resistance gene using a lipofectamine
transfection reagent (Sigma-Aldrich, St. Louis, MO) as described in Chapter 2 of this
study.

Antigens, peptides, and antibodies
Hen egg lysozyme (HEL) was purchased from Sigma-Aldrich (St. Louis, MO).
The mouse HEL74-88 peptide (NLCNIPCSALLSSDI) was produced using Fmoc
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technology and an Applied Biosystems Synthesizer as described [139, 140]. Peptide
purity (>99 %) and sequence were analyzed by reverse phase HPLC purification and
mass spectroscopy. Peptides were dissolved in DMSO and stored at -20℃ until used
[103]. The primary antibodies used were human Bax (B-9), p53, MDM2, CDK4, Cyclin
D, p21, PAX3, c-MET, and GILT, (Santa Cruz Biotechnology Inc., Santa Cruz, CA); and
b-actin (clone AC-15) (Sigma, St. Louis, MO). The secondary antibodies used were
horseradish peroxidase conjugated anti-mouse (Pierce, Rockford, IL, USA), anti-rabbit or
anti-goat IgG (Santa Cruz).

Ganoderic acid DM preparation
Ganoderic acid DM (GA-DM), originally isolated from the Ganoderma lucidum
mushroom, was purchased from Planta Analytica, LLC (Danbury, CT) (Cat# G-032). The
purity of GA-DM was determined by the vendor as 99.9 % using LC/MS analysis. GADM was dissolved in DMSO (Sigma) to make a 10 mM stock solution for use in the
cytotoxicity assay. For all GA-DM treatments, DMSO final concentration was ≤1 %.

Preparation of cell lysates and western blotting
J3.DR4, HT-144.vec, and B16 cells were cultured for 24 hours in the presence of
vehicle alone, 20, or 40 μM of GA-DM. Following treatment, cells were washed and cell
lysate was obtained using a standard lysis buffer (10 mM Trizma base, 150 mm NaCl, 1
% Triton X-100). Equal protein concentrations from designated cell lysates were
separated on a 4–12 % Bis/Tris NuPage gel (Invitrogen, Grand Island, NY). Proteins
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were transferred onto a nitrocellulose membrane (Pierce, Rockford IL), and probed with
antibodies for the expression of Bax, p53, MDM2, CDK4, Cyclin D, p21, PAX3, c-MET,
and GILT. The secondary antibodies used were horseradish peroxidase conjugated antimouse (Pierce), anti-rabbit or anti-goat IgG (Santa Cruz Biotechnology). Monoclonal
antibody for b-actin was used as a protein loading control.

Radiation, GA-DM, and Combination in vitro assays
J3.DR4, HT-144.vec, and B16 cells +/- GILT were grown to 80-90% confluence.
Cells were washed two times with DPBS, trypsinized, and collected in 5ml media. Cells
were spun down at 7000rpm for 5 minutes, media aspirated, the pellet was broken up, and
reconstituted in 2ml of media. Cells were counted and reconstituted as 5x105 cells per
500μl of media in 15ml conical tubes. No treatment cells (Vector-0, GILT-0) were placed
on ice. Multiple radiation treatments were as follows: 5, 10, and 20Gy for appropriate
tubes. After radiation, cells were mixed well, and 100μl of each cell type with each
treatment were plated in triplicate on a flat bottom 96-well plate (cat# 3595, Corning
Incorporated). For GA-DM or combination treatments, GA-DM was then added to
appropriate wells for the final concentrations of 0 and 20μM. An additional 100μl of
media was added to each well, bringing the total volume to 200μl per well. Plates were
incubated for 48 hours or 5 days at 37 °C. After incubation, 50μl of 2.5% trypsin was
added to each well. Plates were incubated 20-30 minutes at 37 °C, and checked under the
microscope to determine if cells had lifted. Using a multichannel pipette, 100μl was
removed from each well and placed in a protein estimation plate. Each well was
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collected and counted using the trypan exclusion method for the number of live cells.
Experiments were repeated at least three times and the data were expressed as percent
cytotoxicity ± SD of triplicate wells.

Annexin V staining and flow cytometry
B16 cells were cultured for 5 days in the presence of vehicle alone, 20μM of GADM, 10Gy radiation, or combination of GA-DM and radiation. Following treatment, cells
were collected and washed with staining buffer (PBS + 1 % heat-inactivated BGS)
(HyClone) 2 times, and resuspended in 1x annexin binding buffer (cat. no. 556454, BD
Bioscience: 0.1 M HEPES (pH 7.4), 1.4 M NaCl, and 25 mM CaCl2) at 1x106cells/ml.
100ul were transferred to individuals tubes were cells were stained with 5ul of Annexin
V-FITC (cat. no. 556420, 556419, BD Bioscience) alone, 5ul of 7-AAD (cat# 5168981E, BD Bioscience)alone, and double staining of annexin V and 7-AAD. Cells were
incubated for 15 minutes at room temperature. 400ul of 1x annexin binding buffer was
added, and samples were transferred to FACS tubes. Samples were then analyzed on a
FACScan using CellQuest software (BD Bioscience, Mountain View, CA) for apoptotic
cells. Experiments were repeated at least three times.

MHC class II antigen presentation assay
B16/Ab cells (5x105cells/ml) were treated with either vehicle alone or 40 μM of
GA-DM for 24 h at 37℃ in culture media in 96-well plate (cat#3595, Corning
Incorporated). The HEL74–88 peptide (10 μM) was added to the appropriate wells for the
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last 4–6 h of incubation as described [139, 140] Cells were then washed and co-cultured
with the HEL74–88 peptide specific mouse T cell hybridoma (BO4) for 24 h. Following
incubation, the plates were stored at -80℃ until tested for mouse IL-2 production. T cell
production of mouse IL-2 was measured by enzyme-linked immunosorbent assay
(ELISA) according to the manufacturer’s instructions (R&D Systems, Minneapolis, MN,
USA). Anti-IL-2 was purchased from Sigma-Aldrich. All assays were repeated at least
three times.

In vivo tumor induction and evaluation
Tumors were induced by the subcutaneous injection of B16 cells (1x105 cells,
>90% viability by Trypan blue exclusion) into the right flanks of 6-8 week old C57BL/6
mice from the Jackson Laboratory. Treatment was initiated by i.p. injection of GA-DM
(25 mg/kg) at day 7 and day 11 for GA-DM only and Combination groups[239].
Localized radiation therapy was initiated at 1.5Gy fractions on days 8, 10, 14, and 16
after tumor injection for 6Gy overall per mouse, using 6 MeV and/or 9 MeV electron
beams from a Varian 2100C linear accelerator located in Radiation Oncology and
administered by personnel in radiation oncology [40]. Following treatment, tumor
volumes were determined at periodic intervals using a digital caliper by measuring the
longest diameter (a) and the next longest diameter (b) perpendicular to (a). Using these
𝜋

measurements, the tumor volume was calculated by the formula: 𝑉 = 𝑎𝑏 2 × 6 [243].
The mice were kept under observation until tumor volume was determined to be 1,400
mm3 or when mice showed signs of severe stress. At this point, the mice were requisitely
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euthanized. Tumor samples were collected to be fixed in 10% formalin, and kept in 70%
ethanol. Serum was collected to be tested for cytokine production, and spleens were
process to be tested for multiple cell populations via flow cytometry. Treatment or
control groups consisted of six mice in experiment #1 and three mice in experiment #2.
All work with mice was approved by the MUSC Animal Protocols Review Board and
was performed in accordance with the National Institutes of Health Guide for Care and
Use of Laboratory Animals.

Statistical Analysis
Data from each experimental group were subjected to statistical analysis.
ANOVA with post hoc tests, Repeated measures ANOVA with post hoc tests or
Student’s t tests were used, as appropriate. Densitometry was measured as described in
Chapters 2 and 3 of this study. Two-sided tests were used in all cases and p values <0.05
were considered statistically significant. Analysis of survival curves was done by the
log-rank test. Parametrical analysis was done using a one-way ANOVA with the
Bonferroni multiple comparison test. The estimates are based on a random effects model
which uses linear regression and random intercepts to account for repeated measures over
time. Comparisons between two groups over time were performed by two-way ANOVA.
Comparisons between two groups were performed by the Student’s t test (parametric) or
Mann-Whitney U test (nonparametric). A p value < 0.05 was considered significant.
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Results
GA-DM treatment upregulates pro-apoptotic Bax proteins in human melanoma cells.
Previous studies have shown that GA-DM treatment may lead to G1 cell cycle
arrest [232, 233]. Although those studies used higher concentrations, the goal for this
study was to determine if a lower concentration of GA-DM may induce apoptotic
proteins in melanoma cells. Therefore, J3.DR4 and HT-144.vec cells were treated with or
without 20µM of GA-DM for 24 hours and then subjected to cell lysate preparation for
western blot analysis. The apoptotic protein Bax was tested, which is an apoptosis
regulator that complements and antagonizes Bcl-2 [239]. In Figure 4.3, cells incubated
with GA-DM displayed a significant increase in Bax protein expression (J3.DR4,
p=0.008; HT-144.vec, p=0.04). This data suggests that GA-DM treatment may induce
apoptotic events in melanoma cells, especially in a lower concentration. However,
further analysis of multiple apoptosis proteins must be examined.
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Figure 4.3 GA-DM treatment upregulates pro-apoptotic Bax proteins in
human melanoma cells. (A) J3.DR4 and HT-144.vec melanoma cells were
treated with 20µM GA-DM for 24 hours, and whole cell lysates were collected
and analyzed through western blot analysis for Bax protein expression. GADM-treated cells expressed significantly higher levels of Bax proteins
compared to untreated cells, as indicated by (B) densitometric analysis. Data are
representative of at least three separate experiments.*p<0.05, **p<0.01.

GA-DM treatment upregulates p53 expression while suppressing MDM2.
Following this hypothetical model, I examined the tumor suppressor protein p53
and its counterpart MDM2. Normally, in unstressed cells, Mdm2 either binds itself to
p53 to inactivate its transport or attaches ubiquitin to p53 to mark it for degradation by
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the proteasome. Oftentimes, melanoma cells do not express p53 through loss-offunction, or p53 is mutated. In Figure 4.4, I tested melanoma cells J3.DR4 and HT144.Vec with or without 24 hour GA-DM treatment (20μM). Cells were lysed, and
protein expression was tested by western blot analysis. As shown, untreated cells
expressed low levels of p53 protein while MDM2 expression was detected. However,
cells treated with GA-DM displayed increased p53 expression while Mdm2 was greatly
reduced. This data suggests that GA-DM treatment may lead to p53-dependent
melanoma cellular death.
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Figure 4.4 GA-DM treatment leads to apoptotic protein activation in human melanoma cells. Cells
treated with 20μM GA-DM showed enhanced p53 expression while Mdm2 was decreased. LNCap, a human
prostate cancer cell line, was used as a p53 positive control. This data suggests that GADM treatment may
lead to p53-dependent melanoma cellular death. Data are representative of at least three separate
experiments.*p<0.05, **p<0.01

GA-DM treatment influences cell cycle checkpoints in human melanoma cells.
Because of the increased p53 protein expression, I then tested the same cell lines
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with the same treatment for expression of Cyclin D, CDK4, and p21. Typically, when
p21 is activated, it blocks the binding interaction between CDK4 and Cyclin D, leading to
cell cycle interruption. Using western blot analysis, it is shown in Figure 4.5 that GADM-treated melanoma cells expressed decreased CDK4 and increased Cyclin D
compared to non-treated cells. In untreated cells, there is a dimer expression, but this is
not seen in GA-DM treated cells. This may be due to the decreased expression of CDK4
observed. Also, there is an increase in p21 protein expression, further proving that this
may disrupt Cyclin D/CDK4 interactions. This data suggests that GA-DM treatment
affects cell cycle checkpoints in melanoma cells.
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Figure 4.5 GA-DM treatment influences cell cycle checkpoints in human melanoma cells. (A) J3.DR4 and HT-144
melanoma cells were treated +/- GA-DM (20μM) for 24 hours and tested for protein expression by western blot analysis.
GA-DM treatment downregulated CDK4 while affecting Cyclin D dimerization in both cell lines. GA-DM also upregulated
p21 protein expression compared to untreated cells. This data suggests that GA-DM affects cell cycle checkpoints in
melanoma cells. (B-D) Densitometric analysis for each protein tested, which was significant in Cyclin D, as indicated by *.
β-actin was used as a loading control.
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GA-DM treatment decreases PAX3 and c-MET proteins in human melanoma cells.
Data presented in the previous chapter suggested that GILT expression
downregulated PAX3 in human melanoma cells. Our lab has previously shown that GADM could influence intracellular machinery of melanoma cells for HLA Class II
processing and presentation to T cells for immune recognition [239]. Therefore, I wanted
to investigate whether GA-DM treatment may also influence tumorigenic molecule PAX3
and its downstream target c-MET, due to their implications in cell survival and possible
metastatic capabilities. Again, human melanoma cell lines J3.DR4 and HT-144.vec were
treated with 20μM GA-DM and tested for PAX3 and c-MET proteins through western
blotting. Figure 4.6 displays GA-DM-treated cells expressed significantly downregulated
PAX3 and c-MET proteins compared to untreated cells (PAX3, p=0.008 & p=0.005; cMET, p=0.001 & p=0.008). This data suggests that GA-DM may influence proteins with
metastatic potential, which further adds to the anti-tumor properties that GA-DM
possesses. Because both GILT insertion and GA-DM treatment may downregulate PAX3
in human melanoma cells, the next step would be to determine whether GA-DM may
influence GILT expression to aid in PAX3 diminution.
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Figure 4.6 GA-DM treatment downregulates PAX3 and c-MET in human melanoma cells. J3.DR4 and HT144.vec melanoma cells were treated with 20µM GA-DM for 24 hours, and whole cell lysates were collected and
analyzed through western blot analysis for PAX3 and c-MET protein expressions. GA-DM-treated cells expressed
significantly lower levels of (A) PAX3 and (C) c-MET proteins compared to untreated cells, as indicated by (B) and
(D) densitometric analysis. β-actin was used as a loading control. Data are representative of at least three separate
experiments.*p<0.05, **p<0.01

GA-DM treatment influences GILT and PAX3 proteins in mouse melanoma cells.
In order to test GA-DM treatment with radiation in vivo, the B16 mouse
melanoma cell line was tested for PAX3 and GILT expression with or without GA-DM
treatment. Unlike human melanoma cells, B16 mouse melanoma cells as well as normal
melanocytes constitutively express PAX3 and GILT If treatment may increase the
expression of GILT in these cells, the implications could be that Ag processing and
presentation is potentially increased, cathepsins activity is enhanced, and that PAX3
inhibition may be occurring. Previous data suggests that human melanoma cells
transfected with GILT displayed an increase in GILT expression when treated with GADM (data not shown). However, this had not been tested in a mouse melanoma cell line
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with constitutive GILT expression. Therefore, after 24 hours of 20μM and 40μM GADM treatment, western blot analysis showed that GILT expression is increased in GADM treated cells compared untreated cells (Figure 4.7). Also, PAX3 expression was
decreased when cells were treated with GA-DM in increasing doses. This indicates that
GA-DM may enhance GILT expression as well as other components of the HLA Class II
pathway while downregulating tumorigenic molecules involved in melanoma like PAX3.
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Figure 4.7 GA-DM treatment influences GILT and PAX3 proteins in B16 mouse melanoma cells. (A) B16 mouse
melanoma cells were treated with 0, 20, or 40µM of GA-DM for 24 hours and tested for PAX3 and GILT protein
expression via western blot analysis. Data suggests a significant decrease in PAX3 expression with GA-DM, while
displaying a marked increase in GILT protein expression. Densitometric analysis for PAX3 (B) and GILT (C) determine
significance as p≤0.05 (*) and p≤0.01 (**).

GILT expression sensitizes melanoma cells to radiation therapy.
PAX3 plays a role in cell survival during melanocytogenesis. However, it is
unknown whether this is true in the development of melanoma. Interestingly, with GILT
decreasing PAX3 expression in melanoma cells, the next step was to determine whether
98

this reduction would allow melanoma cells to be susceptible to cellular death. High-dose
radiation is a common treatment for melanoma patients. Therefore, using lower doses of
radiation through PAX3 targeting would be less toxic to patients. So, in Figure 4.8, I
tested the melanoma cell lines HT-144.vec and HT-144.GILT in a radiation assay using
different doses and incubated for 5 days. Cell viability was examined by the trypan blue
exclusion method. Results show that the presence of functional GILT allowed more cells
to die when compared to vector alone. This data suggests that PAX3 regulation by GILT
sensitizes melanoma cells to radiation.

99

300

*
*

250

*
Viability (x103 cells)

200

**

150

HT-144.Vec
HT-144.GILT

100

50

0

Ctrl

5Gy

10Gy

20Gy

Dose (Gy)

Figure 4.8 PAX3 targeting by GILT allows melanoma cell sensitization by
radiation. Melanoma cell lines HT-144.vec and HT-144.GILT were subjected
to different doses of radiation and incubated for 5 days. Cell viability was
examined by the trypan blue exclusion method. Results show that cells with
GILT were prone to cell death compared to vector alone, indicating that GILT
expression sensitizes melanoma cells to radiation. Data are representative of at
least three separate experiments.*p<0.05, **p<0.01

Mouse B16 melanoma cells were less viable 7 days after radiation treatment.
In order to test in vivo, the mouse melanoma cell line B16 was tested in a
radiation assay as well. After growing B16 to 80-90% confluence, cells were subjected to
varying doses of radiation (5, 10, or 20Gy) and incubated for 7 days. Cells were then
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counted using the trypan blue exclusion method. As seen in Figure 4.9A, cell viability
decreased with increasing doses of radiation. Due to these results, I used the radiation
dose of 10Gy to further test the duration of cell viability. Therefore, B16 cells were
cultured and subjected the cells to 10Gy radiation and incubated for a period of 3, 5, or 7
days and counted cells using the trypan blue exclusion method. In Figure 4.9B, cells
were less viable as incubation increased after radiation exposure.
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Figure 4.9 Radiation influences B16 growth. Mouse melanoma B16 cells were subjected to varying
concentrations of radiation (0-20Gy) and incubated at multiple time points (3-7 days). Cells were collected,
counted, and excluded using trypan blue. (A) B16 cells were exposed to varying doses of radiation and incubated
for 7 days. There is a dose-dependent decrease in cellular viability with increased exposure to radiation. (B) B16
cells were exposed to 10Gy radiation and incubated from 3 to 7 days where a decrease in cell number was observed
with longer incubation. Data are representative of at least three separate experiments.*p<0.05, **p<0.01

GA-DM treatment enhances radiation therapy of human and mouse melanoma cells.
Previous data showed that GILT expression downregulates PAX3, to aid in
sensitizing melanoma cells to radiation therapy in both human and mouse melanoma
cells. It was also found that GA-DM treatment enhanced GILT expression while
decreasing PAX3 expression in both human and mouse melanoma cells. Therefore, I
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wanted to test whether combining these treatments would further enhance cellular death.
First, I tested HT-144 cells with or without GILT expression, and then subjected these
cells to 10Gy radiation, 20uM GA-DM, or the combination of 10Gy with 20uM GA-DM
treatments. Cells were incubated for 5 days, and cell viability was examined by the
trypan blue exclusion method. Results indicate that cells with GILT expression were
prone to cell death compared to vector alone, which was significantly enhanced in the
combination treatment group (Figure 4.10).
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Figure 4.10 Combination treatment increases cellular death in human melanoma cells. Melanoma cell lines
HT-144.vec and HT-144.GILT were subjected to 10Gy radiation, 20uM GA-DM, or the combination 10Gy and
20uM GA-DM treatments and incubated for 5 days. Cell viability was examined by the trypan blue exclusion
method. Results indicate that cells with GILT were prone to cell death compared to vector alone, which was
increased in the combination treatment group. Data are representative of at least three separate
experiments.*p<0.05, **p<0.01

I also tested the B16 cell line using the same treatments, but grown for 7 days
(Figure 4.11). Results show that, again, the combination treatment significantly enhanced
cellular killing in B16 cells compared to radiation and GA-DM alone. This data suggests
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that combination treatment may be a better strategy in killing melanoma cells than single
treatments alone.
*** p=0.00018
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Figure 4.11 Combination treatment enhances cellular death in mouse melanoma cells.
Mouse melanoma B16 cells were subjected to 10Gy radiation, 20uM GA-DM, or the
combination 10Gy and 20uM GA-DM treatments and incubated for 7 days. Cell viability was
examined by the trypan blue exclusion method. Results indicate that cells with GILT were
prone to cell death compared to vector alone, which was significantly enhanced in the
combination treatment group. Data are representative of at least three separate
experiments.*p<0.05, **p<0.01

Combination treatments induce more apoptotic events compared to treatments alone.
In vitro data showed less cell viability in combination treatments among treatment
groups in human and mouse melanoma cells. To investigate the mechanism of this
cellular killing, B16 cells treated with radiation, GA-DM, or combination treatments were
subjected to annexin V staining to determine of cells were undergoing apoptosis. Cells
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were treated with 10Gy radiation, 20uM GA-DM, or the combination of 10Gy with
20uM GA-DM treatments, and cells were then collected on day 5. Cells were stained
with annexin V which binds to the externalized phosphatidylserine during early stages of
apoptosis. Flow cytometric analysis of treated B16 cells (Figure 4.12) show distinct
subpopulations of low forward scatter (FSC) and high side scatter (SSC) profiles
characteristic of apoptotic cells. Further analysis of cells showed higher proportion of the
cells stained with annexin V combining both early and late stage of apoptosis. Apoptotic
cells that double-stained with annexin V and 7-AAD, suggested further entry of 7-AAD
into the apoptotic cells at an early stage where damage to the cell membrane occurred.
Taken all together, data suggests that the combination treated cells led to increased
apoptotic cell death compared to radiation and GA-DM alone.
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Figure 4.12 Combination treatment of GA-DM and radiation induces apoptosis in B16 cells. Contour diagrams of
annexin V-FITC/7-AAD flow cytometry of B16 cells 5 days after (A) no treatment, (B) 10Gy irradiation, (C) 20uM GA-DM,
or (D) combination of both treatments. Dot plot of forward and side scatter (20,000 events/samples, left panels), and annexin
V/7-AAD double staining (right panels) were shown. The quadrant 4 (Q4-1) and quadrant 2 (Q2-1) represent the annexin Vpositive early and late apoptotic cells, respectively.

GA-DM enhances MHC class II-mediated antigen presentation by mouse melanoma
cells.
Our lab has previously shown that GA-DM can enhance HLA class II Ag
presentation to T cells in human melanoma cells. Therefore, I wanted to test this in the
mouse melanoma B16 to further investigate this treatment in vivo. B16/Ab cells were
transfected by the lab of Dr. Ostrand-Rosenberg to express murine MHC class II. This
cell line was given as a gift to our lab, where I tested for Ag processing and presentation
to T cells. Cells were treated with or without 40uM GA-DM overnight and fed with
HEL74-88 peptide. The mouse T cell hybridoma BO4, which recognizes the Ia allele of
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class II with peptide bond on B16/Ab cells, was co-cultured with B16/Ab cells, and
supernatants were collected to test for IL-2 production via ELISA. The production of IL2 is used as an indication of Ag presentation and T cell recognition. Figure 4.13 shows
data shoes that GA-DM treatment enhances MHC class II-mediated Ag presentation and
CD4+ T cell recognition of mouse melanoma cells. This data suggests GA-DM treatment
further increases the CD4+ T cell response of melanoma cells while inducing cellular
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Figure 4.13 GA-DM treatment increases MHC class II-mediated Ag presentation and CD4+ T cell recognition
of mouse melanoma cells. The mouse melanoma cell line B16/Ab was treated with or without 40uM GA-DM for 24
hours and then incubated with HEL74-88 overnight at 37oC. Cells were then washed, and co-cultured with the HEL74-88
peptide specific CD4+ T cell hybridoma line (BO4) for 24 h. T cell production of IL-2 in the culture supernatant was
measured by ELISA. The production of IL-2 is used as an indication of Ag presentation and T cell recognition. Data
are expressed as mean pg/ml +/- SD of triplicate wells of at least three independent experiments. *p<0.01.

Combination treatments significantly increased survival and decreased tumor volume, in
treatment groups in vivo.
In order to investigate the potential therapeutic relevance of my in vitro data, the
effects of the combination treatment, radiation only, and GA-DM only treatments were
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examined in vivo using a B16 mouse melanoma model. Figure 4.14 is a schematic
timeline of the treatments given. C57BL/6 mice were injected with 1x105 cells
subcutaneously in the right flanks.

1x105

Localized
Radiation=1.5Gy
(6.0 Gy Total)

B16 cells are injected S.C. into
C57/BL6 (n=6 per group)
Day -5

Tumor
establishment
Day 0

Day 8

Day 7

• Grow B16
cells in culture.

Day 14

Day 10

Day 16

Day
17-20

Day 11

GA-DM injections
(25mg/kg IP)

•Tumor samples collected for
immunohistochemistry
•Collect tumors, serum, and spleens for
T cell infiltration, macrophages,
cytokines, etc.

Figure 4.14 Schematic timeline of in vivo project for GA-DM and radiation treatments.

Tumors establish 7 days after injection, and GA-DM injections were given on days 7 and
11 at 25 mg/kg through i.p injection. Radiation treatments were given on days 8, 10, 14,
and 16 for 6Gy overall. Tumors were measured as well as well-being of the mice until
tumor volume reached over 1400mm3 or 15% weight loss.
Survival was also calculated in each experiment in vivo, as shown in Figure 4.15.
The Kaplan-Meier curve displays a significant difference in survival overall, based on the
log-rank test (p=0.003). The Combination treatment led to significantly enhanced
survival compared to Control/Untreated and Radiation, p=0.0031 and p=0.049
respectively. There was no significant difference in survival between GA-DM alone
versus Combination treatments. However, there were significant differences in survival
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when comparing Control/Untreated with Radiation and GA-DM (p=0.02 and p=0.011,
respectively). Table 4.2 summarizes the survival differences among treatment groups.

Figure 4.15 Combination and GA-DM groups displayed significantly
prolonged survival among treatment groups. Kaplan-meier curves chart
the survival for treatment groups. Overall survival was significant
compared to the untreated group (p=0.003, log-rank test). The Combination
treatment group displayed significantly enhanced survival compared to
Untreated and Radiation groups (Untreated vs. Combo, p=0.0031, Radiation
vs. Combo, p=0.049), although survival between GA-DM and Combo was
not.
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Table 4.2 Statistical Analysis of Survival among Treatment Groups.
Group 1

Group 2

p-value

Combination (black)

Control/Untreated (blue)

0.0031

Combination (black)

Radiation (green)

0.049

Combination (black)

GA-DM (red)

0.24

GA-DM (red)

Control/Untreated (blue)

0.011

Radiation (green)

Control/Untreated (blue)

0.02

GA-DM (red)

Radiation (green)

0.51

Values were calculated on the log-rank test, p<0.05 were considered statistically
significant.
In Figure 4.16, it was found that tumor volume was significantly reduced in the
combinations treatment group at days 12 and 16, when compared to untreated, radiation
only, and GA-DM alone (Tables 4.3, 4.4).
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Figure 4.16 Combination treatment reduced tumor volume in vivo. Each line represents the tumor volume of
one mouse for each treatment group. Tumor volume was delayed in the combination group compared to GA-DM
and radiation alone. N=8, Control & GA-DM; N=9, Radiation & Combination
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Figure 4.17 Combination treatment reduced tumor volume in vivo. A representative picture of one mouse per
treatment group with appropriate tumor volume is displayed at days 7, 14, and 16.

Representative pictures were taken of one mouse per group to display increased tumor
growth (Figure 4.17). The estimated tumor growth curves over time was graphed using a
random effects model, which utilizes linear regression and random intercepts to account
for repeated measures over time (Figure 4.18). Fold change in the tumor volume was
also calculated among treatment groups. Inferences were based on days 12 and 16, where
the fold change of the combination tumor volume was significantly lower compared to
radiation and GA-DM groups at days 12 and 16, while combo and control was significant
at day 16, shown in Figure 4.19.
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Figure 4.18 Estimated tumor growth curves per group over time. The estimates are based
on a random effects model which uses linear regression and random intercepts to account for
repeated measures over time. Due to the non-linear patterns, quadratic terms were included to
account for curvature. Due to non-linearity, slopes cannot be compared. Two experiments were
included: there is an experiment effect included in the regression model, the lines indicate
experiment 1 (solid) vs. experiment 2(dashed).
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Figure 4.19 Fold change in tumor volume among treatment groups. Inferences were based on
days 12 and 16. Statistical analysis suggests that the fold difference between Combo and Radiation
and GA-DM treatment groups were significant at days 12 and 16, while Combo and Control was
significant at day 16 (Tables 4.1 & 4.2).
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Table 4.3 Tumor volume fold difference at Day 12.
Group 1

Group 2

p-value

Radiation (red)

Day 12:
Fold difference in tumor size
(group 2/group 1)
1.90

Control/Untreated
(black)
Control/Untreated
(black)
Control/Untreated
(black)
Radiation (red)

GA-DM (green)

1.60

0.17

Combo (blue)

0.64

0.18

GA-DM (green)

0.84

0.59

Radiation (red)

Combo (blue)

0.34

0.0011

GA-DM (green)

Combo (blue)

0.40

0.0055

0.064

Inferences are based on comparing fitted tumor size at 12 days. Due to non-linearity, slopes
cannot be compared.

Table 4.4 Tumor volume fold difference at Day 16.
Group 1

Group 2

p-value

Radiation (red)

Day 16:
Fold difference in tumor size
(group 2/group 1)
0.89

Control/Untreated
(black)
Control/Untreated
(black)
Control/Untreated
(black)
Radiation (red)

GA-DM (green)

0.88

0.68

Combo (blue)

0.32

0.0011

GA-DM (green)

0.98

0.96

Radiation (red)

Combo (blue)

0.36

0.0019

GA-DM (green)

Combo (blue)

0.37

0.0027

0.71

Inferences are based on comparing fitted tumor size at 16 days. Due to non-linearity, slopes
cannot be compared.

This data supports the previous data shown that combination treatments
significantly reduce tumor burden. Altogether, this data suggests that the radiation/GA114

DM combination therapy possesses several antitumor properties that make it an attractive
candidate for the development of novel therapeutic strategies.

Discussion & Conclusions
A defining feature of conventional anticancer therapies is their capacity to evoke
cellular death by inducing cell apoptosis [239]. However, inherent or acquired
resistances of cancer cells to mainstay treatments have been a major obstacle to complete
treatment and sufficiently prevent tumor reoccurrence. Therefore, the search for new
natural drugs that sensitize cancer cells to chemotherapy-mediated apoptosis, while also
restoring antitumor immunity has increasingly become a focus of investigation [232, 239,
244]. This chapter shows that G. lucidum-derived triterpenoid GA-DM displays
profound antitumor properties through alterations of cellular signaling and induction of
apoptosis. GA-DM treatment leads to a p53-dependent apoptotic pathway, through
multiple cell cycle checkpoints. It was also found GA-DM treatment enhanced GILT
expression while downregulating PAX3 expression in B16 mouse melanoma cells, a
similar trend found in human melanoma cell lines. This is further enhanced when
combining with the mainstay treatment of radiation.
On the other hand, in the previous chapter, it was shown that functional GILT
downregulates PAX3. Many studies have shown that targeting PAX3 leads to cell
becoming susceptible to cellular death [206, 219]. Therefore, radiation treatment was
used on both human and melanoma cells to determine cellular death. Results indicated
that GILT expression led to enhanced killing of human melanoma cells compared to non115

GILT cells. B16, which naturally expresses GILT, also displayed increased cellular death
with increasing doses of radiation. This suggests that the insertion of GILT in melanoma
cells may lead to increased susceptibility for treatments. Combining radiation with GADM further enhanced cellular death in both human and mouse melanoma cells in vitro,
compared to radiation and GA-DM alone. Annexin V staining supported this finding that
combination treatments enhanced apoptosis in B16 cells compared to treatments alone.
This promotes the efficacy of combining GA-DM treatment on melanoma cells with
radiation therapy, utilizing the bioradiotherapy strategy.
Also, high-dose radiation and immunotherapies have proven to be highly toxic to
patients with low response rates [194]. Thus, treatment strategies have been adopted to
combine chemotherapy with immunotherapy to destroy cancer cells as well as elevate
antitumor immunity to prevent further re-occurrence [245]. An agent that could enhance
tumor immunogenicity while reducing tumor burden would be an ideal
chemoimmunotherapeutic to overcome major obstacles in melanoma treatment [239].
Evidently, low concentrations of GA-DM have shown a much stronger effect in inducing
an immune response, where surviving cells were capable of processing whole Ags for
presentation to T cells. This chapter also highlighted that GA-DM enhanced MHC class
II-mediated Ag presentation to CD4+ T cells in mouse melanoma cells. In order to
investigate the potential therapeutic relevance of my in vitro data, the anti-tumor
properties of GA-DM combined with radiation were examined in vivo using a B16
melanoma mouse model. I found that the administration of GA-DM combined with
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radiation treatment significantly reduced tumor volume among treatment groups, which
also significantly increased survival.
This study suggests that the radiation/GA-DM combination treatment makes for
an attractive candidate for the development of novel therapeutics. GA-DM induced an
upregulation of MHC class II that may prove to enhanced Ag presentation and T cell
recognition of target cancer cells, confirming our previous findings in human melanoma
cells. The beneficial effects of GA-DM with radiation were shown in vivo as evidenced
by the significant decrease in tumor volume with significant increased survival.
Current treatments for metastatic melanoma include surgery, chemotherapy, highdose radiation, and some immunotherapies. However, these treatments appear futile once
the tumor has metastasized beyond localized lymph nodes. This stresses the need for
improved disease targeting as well as new possibilities for combining treatments.
Importantly, PAX3 plays a vital role in anti-apoptotic events during melanocyte
development, and thus, targeting this tumorigenic protein may lead to a less aggressive,
less metastatic form of melanoma. By targeting PAX3, melanoma cells may be
susceptible to different types of treatments. [239]. Therefore, testing these treatments in
vivo may reveal potential in using radiation-GA-DM combination treatment as a
chemoimmunotherapy for treating metastatic melanoma.
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Chapter 5: Summary and Conclusions
Metastatic melanoma is an aggressive disease that has been plaguing Western
populations for many year. Finding a tolerable and effective treatment for melanoma has
proven to be difficult. Current studies examining immunotherapies with common
treatments have shown to provide the necessary boost to further improve tumor killing.
The main goals of this dissertation were to examine the role of GILT in melanoma cells,
determining the effect of GILT upon a known tumorigenic protein in metastatic
melanoma, and investigating combination therapies to help combat this disease.
Data from the first aim of this study suggests multiple roles of GILT when present
in melanoma cells. Although GILT’s major role is in the catalysis of disulfide bonds
formed between cysteine residues, it has been shown that GILT may also enhance
cathepsin expression and activity. Localized in the endosomal/lysosomal compartments,
it was found that GILT colocalizes with cathepsin B and D, which can lead to enhanced
Ag processing and presentation. Bioassays testing for cathepsin activity confirmed this
finding. With enhanced cathepsin activity, Ags undergo further splicing and processing
to result in reduced, more functional peptides. These functional peptides can then be
readily loaded onto HLA class II complexes to be presented and recognized by CD4+ T
cells.
Because of enhanced cathepsin expression and activity with the presence of
GILT, data acquired from mass spectroscopy suggests that GILT may aid in generating a
greater pool of reduced, functional peptides and epitope generation. A greater pool of
reduced IgGκ188-203 peptide was present in J3.DR4.GILT cells as compared to J3.DR4.vec
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cells, confirming GILT’s ability to functionally reduce antigenic peptides needed for T
cell recognition. In comparing GILT-positive to GILT-negative cells, cells with GILT
expression were producing 44.7% tri-oxidized cysteine-containing peptides, which was
significantly lower than 77.9% tri-oxidized cysteine-containing peptides generated from
GILT-negative cells. With more functional peptides available, these peptides can be
loaded onto class II molecules in presentation to CD4+ T cells, where we see enhanced
IL-2 production from T cells. Enhancing presentation to the adaptive immune system can
be exploited in a new immunotherapy approach, such as a whole cell vaccine strategy, as
well as establishing memory in recurring malignant melanoma cells.
Results presented in the second aim of this dissertation also propose a new target
and mechanism for late stage metastatic melanoma. The tumorigenic molecule PAX3 has
been implicated in melanoma progression and metastasis. Data obtained showed that
GILT decreases PAX3 protein expression. Confocal microscopy determined that this
downregulation occurred through the colocalization of GILT and PAX3; this was
confirmed that GILT and PAX3 have a protein-protein interaction through
immunoprecipitation. Importantly, when using a GILT mutant transfected into the J3
melanoma cell line, functional GILT was required for PAX3 downregulation. GILT also
was shown to enhance Daxx protein expression, a key regulator of PAX3. The elevated
Daxx expression and the direct interaction with GILT may cause PAX3 downregulation.
Also, GILT and Daxx may utilize the STAT1 pathway to regulate PAX3. Further studies
will be conducted to determine how Daxx plays a role in the regulation of PAX3 when
GILT is present.
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This thesis also investigated the mechanism by which GILT is able to affect
PAX3 expression. PAX3 has expression in both the nucleus and the cytosol, dominantly
in the cytosol [87]. However, GILT's location is in the endosomal/lysosomal
compartments. Data suggests that GILT is leading PAX3 to a lysosomal degradation
fate. Because of GILT insertion, autophagic proteins like Beclin-1 and LC3 are
influenced, and blocking lysosome function via bafilomycin allowed PAX3 proteins to
endure in human melanoma cells with or without the presence of GILT. This suggests
that GILT regulates PAX3 expression through the autophagy and lysosomal degradation
pathway. Future studies of this aim may examine adapter proteins like heat shock
proteins. These molecules are known for chaperoning other molecules and may be
studied to determine how PAX3 relocates throughout the cell. Also, the PKC protein
family may be studied as they have the ability to bind other signaling proteins, and they
also have a role in modulating cellular processes such as vesicle trafficking and cell-cell
communication [133]. Exploration of the autophagy and lysosomal degradation pathway
may be examined to determine another role of GILT when present in melanoma cells.
This aim showed that PAX3 is linked with late stage metastatic melanoma and is
susceptible to targeted therapy. Such possibilities include using siRNA to block PAX3
transcription or using a cytotoxic drug targeting PAX3 to block its expression.
Aim three of this study investigated different therapeutic options to test upon both
human and mouse melanoma cell lines and in vivo. GA-DM is a triterpenoid extract from
G. lucidum that has many anti-proliferative properties, engaging intracellular signaling
pathways, and induction of apoptosis. Apoptosis, a mechanism of programmed cell death,
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is thought to be an important mechanism in tissue homeostasis [244]. This study outlined
a model/signaling pathway that GA-DM treatment may lead melanoma cells through to
induce apoptosis. Results from this thesis indicated that cells treated with GA-DM were
lead to cellular death in a p53-dependent pathway. Cells with GA-DM treatment also saw
a significant decrease in PAX3 expression in human and mouse melanoma cells.
Importantly, GA-DM treatment significantly enhanced GILT expression in mouse
melanoma cells. This increased expression of GILT by GA-DM may lead to an enhanced
downregulation of PAX3. Allowing a downregulation of PAX3 may lead to
susceptibility for melanoma cells to cellular death as well. On the other hand, melanoma
cells that expressed GILT were also susceptible to radiation therapy compared to GILTnegative cells. This novel finding suggests that by treating melanoma cells with the
combination of radiation with GA-DM, enhanced killing of melanoma cells may prove
positive results in vivo.
B16 cells displayed susceptibility to both radiation and GA-DM treatment. These
treatments also displayed a decrease in PAX3 expression while upregulating GILT. B16
cells transfected with MHC class II expression were also treated with GA-DM, and IL-2
was increased with GA-DM treatment compared to untreated cells. These findings led
me to investigate whether the combination treatment may be beneficial in a mouse model.
Therefore, using B16 in C57BL/6 mice, various treatments were tested to determine
efficacy. Results indicated that the combination treatment increased survival and
significantly reduced tumor volume among treatment groups. This study shows that
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utilizing a combination treatment strategy may further enhance killing while inducing an
immune response for potential memory for recurring cancer cells.
Future studies for this aim will investigate the immune components of the
combination therapy in vivo. T cell infiltration will be examined within the tumor tissue
among treatment groups at different time points. Previous studies in our lab have shown
that T cells invade the tumor tissue by day 17 when mice were treated with 50 mg/kg
GA-DM. It would be interesting to determine whether combination therapy may help in
this aspect to help combat tumor growth. Other experiments will also look into the
macrophage population within tumor tissue. Tumors may be examined via
immunohistochemistry to determine the M1 versus M2 population of macrophages.
Currently, the paradigm is that M1 macrophages express markers on the cell surface to
suppress cancer progression while M2 macrophages promote it. Determining this facet
within the tumor microenvironment, supported by serum cytokine expressions, may aid
in the effectiveness that the combination therapy may have in vivo. Future studies for this
project will also include optimizing multiple doses of both GA-DM and radiation
therapy. This will help define the best overall dosage for both treatments by promoting
tumor killing without cytotoxicity for the patient.
This study determined that combination treatments make for interesting
candidates for the development of novel immunotherapeutics. If these strategies were
used, we would hope to see a reduction in the aggressiveness and metastatic nature of
melanoma cells. This study provides further insight into the complex nature of
melanoma, and how novel targeting strategies are needed to combat this deadly disease.
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